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ABSTRACT 
Background: Heparin is the standard anticoagulation used to prevent clotting in the 
extracorporeal circuit during hemodialysis. Its anticoagulation effect can be measured by 
the activated clotting time (ACT), to achieve 1.5- 2 times the baseline value to prevent 
clotting or bleeding during hemodialysis. However, it is unknown whether changing ACT 
monitoring policy in chronic hemodialysis patients, from routine monthly ACT 
monitoring to ACT measurement in response to clinical events, will increase the risk of 
clotting and bleeding events. 
Methods: To evaluate, in chronic hemodialysis patients on a stable heparin dose, whether 
a change in practice, from routine monthly ACT monitoring (Phase I) to one in which 
ACTs are only measured for initial dose assignment or in response to clinical indications 
(Phase II), will significantly increase the incidence of patients' bleeding or clotting 
events, 109 patients in our hemodialysis unit were followed and evaluated for 8 months in 
a quality initiative study using a before-and-after design. Clotting event was defined as 
visible signs of clot formation in the bottom of the dialyzer, coagulated dialyzer, or 
changing the circuit due to clotting. Overt bleeding documented by clinical examination 
or diagnostic investigations within 4 hours from hemodialysis session, doubling 
homeostasis time in patients with A VF; not secondary to fistula-related issues, 
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unexplained fall in hemoglobin 2: 20 g/L within a month, or the requirement for blood 
transfusion due to bleeding were defined as a bleeding event. 
Results: The mean ACT in phase I was higher than phase II (P =0.003), but >50% of 
ACTs were below target. Although heparin doses were changed more often (Incident rate 
ratio (IRR) 9.11; 95% CI: 2.78-29.92, P =0.000), and more effectively achieving ACT 
target during phase I compared with phase II (IRR 189.5; 95% Cl: 25.36-1415.2, P 
=0.000), the incident rate ratio for all clotting events occurred during phase I was 
unexpectedly and significantly higher (IRR 1.4; 95% CI: 1.01-1 .97, P =0.041) than phase 
II. For unclear reasons, the risk of any clotting event occurring during phase I was higher 
than phase II (Odd Ratio; OR 1.87; 95% CI: 1.03-3.39, P =0.04). This could not be 
explained merely by the low frequency and effectiveness of heparin dose changes, which 
occurred in less than 10% of clotting events, and were effective achieving ACT target in 
only 50% of above cases. Although heparin doses were changed more often when serious 
clotting (type 2 or 3) occurred during phase I compared with phase II, heparin change was 
not statistically significant (OR 3.12; 95% CI: 0.62-15 .8, P =0.17), nor was it effective in 
achieving ACT target (OR 2; 95% Cl: 0.08-51 .6, P =0.68). 
Bleeding events occurred 6% less often during phase I compared with phase II. However, 
this was not statistically significant (P =0.84), although the risk for any bleeding event 
stayed the same during both phases (OR 1; 95% CI: o.53-1.9, P =1). 
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Conclusions: Routine monthly ACT monitoring in adult chronic hemodialysis patients did 
not improve clinical outcomes reducing clotting and bleeding events compared with 
measuring ACTs only for the initial dose assignment or in response to clinical indications. 
However, as practiced locally, this could be due to the limited physician response to 
ACTs that were not at target. 
To more thoroughly address the question of whether routine ACT monitoring is 
necessary, the best approach in a future randomized trial would include strictly 
standardized heparin dose-adjustment protocols to be used routinely by hemodialysis 
nurses to reduce the potential for bias due to physician response variability. 
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INTRODUCTION 
Hemodialysis is an important mode of therapy in the treatment of patients with acute 
kidney injury (AKI) and end stage renal disease (ESRD). While blood is exposed to 
dialyzer membranes during hemodialysis, platelets adhere to the artificial surface, 
resulting in activation of the coagulation cascade and platelets ( I). As a result of this 
activation, blood clotting in the dialyzer and dialysis machine circuit may occur. Dialyzer 
clotting may lead to decreased efficiency of treatment and loss of blood by the patient (2). 
Hypercoagulability may be present in hemodialysis patients secondary to predialysis 
elevated levels of coagulation proteins such as thrombomodulin and thrombin-
antithrombin (TAT) complex (3. 4). Therefore, to prevent clotting in the extracorporeal 
circuit during hemodialysis, anticoagulation is usually required. Furthermore, 
anticoagulation monitoring during hemodialysis may be indicated to reduce the risk of 
clotting and bleeding events. 
Unfractionated heparin is a mixture of glycosaminoglycans, with molecular weight 
between 3 and 30 kilo Daltons (kDa) that indirectly inhibits thrombin (5,6). One-third of 
unfractionated heparin molecules randomly contain a pentasaccharide sequence that binds 
to antithrombin III (AT -III), converting AT -III to a rapid inactivator of thrombin, factor 
Xa and other active coagulation factors, thus inhibiting the clotting cascade and 
preventing clotting (5,6). The anticoagulant effect of unfractionated heparin can be 
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measured by plasma-based activated partial thromboplastin time (aPTT), which measures 
the increased time taken for clot formation under controlled conditions (6). This 
anticoagulant effect of unfractionated heparin can also be measured by faster, bedside 
methods such as the whole blood activated partial thromboplastin time (WBPTT) (7) and 
the whole blood activated clotting time (ACT) (~) . A rise in the WBPTT or ACT to 1.5-
2 times the baseline value is usually acceptable to provide sufficient anticoagulation with 
unfractionated heparin (7, 8). 
Use of heparin is the standard of practice for anticoagulation during hemodialysis in 
most countries; it is relatively inexpensive and most hemodialysis machines are 
equipped with a heparin infusion pump (6). We presently use heparin for anti-
coagulation during dialysis. When initiating a patient on dialysis, a dose of heparin is 
prescribed and the effect on ACT is measured. Once an individualized patient dose has 
been determined to get the patient to the target ACT, the same dose is given for all 
subsequent dialyses. Anticoagulation with heparin is routinely performed with a loading 
dose (approximately 15-70 IU/kg) given through the venous port; three to five minutes 
prior to hemodialysis; followed by a continuous infusion (500-1500 IU/hr) (6, 9-13). To 
achieve an adequate anticoagulation without increasing the risk of bleeding, heparin 
infusion is generally stopped at the end of hemodialysis session unless the patient has an 
A V fistula, in which case, heparin infusion is usually stopped 30-60 minutes prior to the 
end of hemodialysis to limit bleeding on needle removal ( 14). Complicated mathematical 
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modeling can predict the required heparin dose during hemodialysis to reduce the risk of 
bleeding, but those models are inconvenient and not widely used ( 15, 1 (l ) . 
Other potential anticoagulation agents that can be used during hemodialysis to prevent 
clotting in the extracorporeal circuit during hemodialysis are low molecular weight 
heparin, citrate, prostacyclin, and recombinant hirudin anticoagulation. 
Low molecular weight heparin (LMWH), like unfractionated heparin, inactivates clotting 
factor Xa, though it has a lesser effect on thrombin since most of the LMW heparins do 
not contain enough saccharide units to bind to thrombin and antithrombin III (AT-III) . 
LMW heparins have been proposed to result in less thrombocytopenia and bleeding than 
unfractionated heparin ( I 7, 18), although there is extensive cross reactivity (> 90%) 
between the LMWH and unfractionated heparin in terms of thrombocytopenia and 
hypercoagulable state once a patient develops heparin-induced thrombocytopenia (HIT). 
Although the cost of LMWH varies across countries, LMW heparins are still expensive in 
North America and have not been associated with less hemodialysis-related bleeding, 
thrombosis, or other complications compared with unfractionated heparin ( 17, 18). 
Furthermore, monitoring LMWH with the activated partial thromboplastin time (aPTT) is 
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not accurate, and usually requires the measurement of anti-factor Xa levels, which is 
more expensive and less available ( 19 .20). 
The regional citrate anticoagulation regimen has been adopted in many hemodialysis 
units as an alternative method of anticoagulation in patients on chronic hemodialysis, 
especially when heparin use is contraindicated (21 ). The regional citrate anticoagulation 
regimen involves the continuous infusion of isosmotic trisodium citrate solution into the 
arterial side of the dialyzer (21 ). Trisodium citrate binds to patient ' s plasma calcium, 
inducing a decrease in the patient's free plasma calcium concentration, inhibiting the 
progression of the coagulation cascade. The citrate infusion rate is adjusted to keep the 
ACT above 200 seconds in the arterial limb. 
Later, the citrate-calcium complex is removed across the dialyzer and the regional 
anticoagulation is reversed by the infusion of 5% Calcium citrate solution into the venous 
return line at adjusted rates according to the patient' s plasma calcium concentration (22). 
Although trials have showed lower bleeding incidence rates associated with the regional 
citrate anticoagulation compared with the standard heparin protocols (23.24), the regional 
citrate anticoagulation has been associated with major electrolyte abnormalities 
(hypocalcemia, hypercalcemia, or hypernatremia) and metabolic alkalosis that limited its 
use in patients on chronic hemodialysis. 
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The Citric acid-based dialysate ( Citrasate ®) results in reduced clotting in no-heparin 
dialysis, by lowering patient's serum calcium enough to interfere with the clotting 
cascade without inducing symptomatic hypocalcemia or metabolic alkalosis (15,26). 
However, a small but significant change in the patient's serum calcium is a major 
complication of citrate dialysate. More trials are required to identify the safety and 
effectiveness of the use of citrate dialysate in chronic hemodialysis patients. 
The arachidonic acid metabolite prostacyclin is a vasodilator and inhibitor of platelet 
aggregation. Prostacyclin regional anticoagulation involves a continuous infusion of 
prostacyclin into the dialyzer circuit during hemodialysis to prevent platelet aggregation 
and clotting (27). Side effects include headache, lightheadedness and facial flushing. 
However, its use during chronic hemodialysis has been limited by its expense as well as 
its side effects including headache, facial flushing, and most importantly hypotension due 
to vasodilation (2~) . 
Hirudin inhibits thrombin by forming a noncovalent complex. Recombinant hirudin 
(lepirudin) has been used in hemodialysis patients as a single bolus at the beginning of 
hemodialysis or as a continuous infusion (29.30). However, due to its prolonged half-
time in hemodialysis patients, its use has been limited (29,30). 
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Although heparin has been widely used during hemodialysis as an anticoagulant, 
and although studies have shown an improvement in dialysis efficiency (2) associated 
with the anticoagulation effect of heparin, there is no standardized approach to 
heparin dosing or monitoring during hemodialysis (6). Furthermore, searching the 
available literature could not identify an evidence-based protocol reconm1ending ACT-
guided heparin monitoring and dosing during chronic hemodialysis. Consequently, a 
quality initiative study was required to test whether an increased risk of clotting or 
bleeding would follow the change in ACT monitoring policies. 
From a clinical practice approach, the majority of hemodialysis units in North America 
approve the continuous infusion regimen of unfractionated heparin during hemodialysis 
in patients with end stage renal disease and no contraindication for heparin. This regimen 
is generally delivered; as mentioned above; as a bolus followed by continuous infusion (6. 
9-13 ). A prolongation of the aPTT, WBPTT, or ACT to 150% of their pre-dialysis values 
is reconm1ended to provide sufficient anticoagulation without increasing the risk of 
bleeding (7 . ~). ACTs are readout by automated machines in the dialysis unit, which are 
faster and more favorable than the other two tests (5). Some dialysis units, ours currently 
included, routinely measure ACTs on all patients on a monthly basis. This is done even 
in the absence of any indication of a clinical problem with bleeding or clotting. Minor 
adjustments to the heparin dose are sometimes made once the ACT results are reviewed. 
It is not clear that this leads to any improvement in patient outcomes, but the whole 
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process of measuring ACTs routinely is resource and staff time intensive. In contrast to 
our practice, many other hemodialysis units (e.g. The Ottawa Hospital, Ottawa, Ontario, 
Canada) do not routinely measure ACTs again on patients for whom a suitable dose of 
heparin has been identified and who are not showing any indication of either bleeding or 
clotting problems. However, there are no available studies or evidence to support the 
latter practice. 
On the other hand, heparinization during hemodialysis has been associated with multiple 
hemorrhagic complications (such as subdural hematoma (31 ), retroperitoneal (32) and 
pleural (33) hemorrhage) in hemodialysis patients that could be complicated by death in 
3-5% of cases (34, 35). Additionally clotting can diminish the efficiency of dialysis and 
lead to patient blood loss (2). Therefore, both bleeding and clotting have negative effects 
on patients and have cost impacts for the health system. Accordingly it is important to try 
to get the best balance between the risk for bleeding and clotting while using 
anticoagulants for hemodialysis. 
Aim of Study: 
The purpose of this Quality Improvement Exercise was to evaluate, in chronic 
hemodialysis patients on a stable dose of heparin, whether a change in practice from 
routine monthly monitoring of ACTs to one in which ACTs were only measured for 
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initial dose assignment or in response to clinical indications, will lead to any significant 
increase in patients' bleeding or clotting events. Furthermore, if no such safety concerns 
are identified, the plan would be to save or reassign resources by discontinuing our 
current practice of routine monthly ACT monitoring. 
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LITERATURE REVIEW 
Although heparin has been widely used during hemodialysis as an anticoagulant, and 
although studies have shown an improvement in dialysis efficiency (2) associated with 
the anticoagulation effect of heparin, there is no standardized approach to heparin 
monitoring and dosing in chronic hemodialysis patients on a stable heparin dose (6 ). 
Searching the current available literature using the following synonymous terms (renal 
failure , end stage renal disease, ESRD, chronic hemodialysis, renal replacement therapy, 
anticoagulation, heparin, unfractionated heparin, monitoring and activated clotting time; 
ACT), using the following sources (The Cochrane Library, MEDLINE/PubMed!MeSH, 
Uptodate, ASN (American Society of Nephrology), Journals (JASN, CJASN, KI, NOT, 
etc), Textbooks, Experts opinion, and google.com), looking at (Randomized Controlled 
Trials, Systematic Review, Meta-analysis, practice guideline, and clinical trials) in the 
light o[the fo llowing limits (English language, adult, age ~ 19 year, end stage renal 
disease, chronic hemodialysis, and human model); could not identify any randomized 
controlled trial (RCT), systematic review, meta-analysis, or clinical trial that investigates 
ACT- guided heparin monitoring and dosing during chronic hemodialysis. 
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Multiple practices are currently used to dose unfractionated heparin for chronic 
hemodialysis. Heparin can be delivered during chronic hemodialysis as a continuous or 
intermittent bolus ( 6. 9-13 ). Continuous administration provides a predialysis loading 
dose, followed by a constant infusion of heparin during hemodialysis. Intermittent 
administration consists of one or more bolus doses (6.9-13). 
Depending on the pharmacodynamics of unfractionated heparin, the continuous 
administration of heparin during chronic hemodialysis, as described above, provides a 
more uniform level of anticoagulation than the intermittent administration (()). However, 
due to the wide variability in the pharmacodynamics ofunfractionated heparin from one 
patient to another, the use of the same heparin dose for all patients during chronic 
hemodialysis will result in excessive or inadequate anticoagulation (6,9). Subsequently, 
to provide excellent control of anticoagulation and to determine heparin dosing in 
hemodialysis patients, multiple clotting times (WBPTT or ACT) and careful dose 
adjustments are required ( 16), especially at the initiation of hemodialysis to establish the 
target heparin dose. An increase in the WBPTT or ACT to 1.5- 2 times the baseline value 
is generally thought to provide adequate anticoagulation with unfractionated heparin (6). 
However, the same type of assay may provide different results depending on the 
measurement machine and the activating standard used (6). The above practice is also 
expensive, labor intensive, and unsuitable to busy hemodialysis units. 
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Complicated mathematical modeling, which requires the use of a computer-controlled 
heparin infusion pump, can predict the required heparin dose during hemodialysis to 
reduce the risk of bleeding, but those models are inconvenient and not widely used ( 15, 
16). 
Given the difficulties outlined above, there is no standardized approach to heparin 
monitoring and dosing in chronic hemodialysis nor there are evidence-based protocols, 
reconm1endations, or guidelines to recommend routine monthly clotting times (ACT) in 
chronic hemodialysis patients to monitor heparin dosing in order to reduce major heparin-
related complications. From a clinical practice approach, some dialysis units in North 
America, ours currently included, routinely measure ACTs on all patients on a monthly 
basis, even in the absence of any clinical indication of bleeding or clotting. Minor 
adjustments to the heparin dose are sometimes made once the ACT results are reviewed. 
However, it is not clear that this leads to any improvement in patient's outcomes. In 
contrast to our practice, many other hemodialysis units do not routinely measure ACTs 
again on patients for whom a suitable dose of heparin has been identified and who are not 
showing any indication of either bleeding or clotting problems. However, as reported 
above, there are no available studies or evidence to support either practices over the other 
at this time. 
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METHODS 
This evaluation was done in our hemodialysis unit at the Waterford Hospital, in St. 
John 's, Newfoundland and Labrador, in Canada, after our research proposal was 
approved by the Human Investigations Conm1ittee (HJC # 09.111) and the Research 
Proposals Approval Conm1ittee (RP A C) of Eastern Health. This hemodialysis unit 
provides hemodialysis to 100-120 stable ambulatory adult patients, six days a week, in 
three daily shifts and is geographically suitable for collection of the data required for this 
evaluation. Since both practices (routine monthly ACT monitoring versus ACT 
monitoring as indicated) have been adopted by several dialysis units in North America, 
and since this evaluation was considered a quality improvement exercise, we proposed 
not to request an individual patient consent. We planned the evaluation as a before-and-
after design. In the first four months (Phase I), we continued our current practice of 
monthly monitoring of ACTs while collecting data on bleeding and clotting events. In 
the subsequent four months (Phase II), we changed our practice to that of measuring 
ACTs for clinical indications only while collecting data on bleeding and clotting events 
when these occurred. We informed all staff and patients of the change at the time. 
All patients in our hemodialysis unit on established doses of heparin during hemodialysis 
were enrolled in this study, unless they had contraindication to heparin. Patients not 
receiving heparin for any reason were excluded. For the first four months (Phase I), all 
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patients received monthly ACT and heparin dose was supposed to be adjusted by the 
Nephrologist covering our hemodialysis unit depending on ACT values and as per our 
current protocol (Appendix A & B). For the following four months (Phase II), no patients 
had monthly routine ACTs. ACTs were only done if clinically indicated. In the event of 
a clinical problem, heparin dose was only adjusted, by the Nephrologist covering the 
hemodialysis unit, depending on a stat or scheduled ACT. 
The dialysis nurses were instructed as to what constitutes a bleeding or clotting episode 
that they should note and record in patient's record (Please refer to prima~y and 
secondary endpoints ' definition below). Throughout the eight months of the evaluation, 
clotting and bleeding events were evaluated and recorded in the patients' written and 
electronic dialysis charts, by the hemodialysis nurses as a part of their routine intra- and 
post-hemodialysis evaluation. At the end of the evaluation, patients ' results and data 
were reviewed, collected, and analyzed by Dr. Shamseddin. 
Meanwhile, to ensure the completeness and accuracy of the data recording, ongoing 
education to the nursing staff was provided to correctly identify, collect, and record 
primary and secondary end points. Periodic checks were done by Dr. Shamseddin to 
secure identifying and recording of all events. Identifying and recording events as a part 
of routine intra- and post-hemodialysis evaluation of hemodialysis by the nurses, was the 
most dependable means available to capture all primary and secondary events especially 
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the ones occurring during or shortly after hemodialysis sessions prior to patients departing 
the hemodialysis unit. 
There was no specific budget for this study. The cost of hemodialysis, heparin, and 
routine monthly ACTs were all part of our standard current practice. Recording the 
clinical bleeding and clotting events was also part of our standard practice. Data retrieval 
and analysis were completed by Drs. Shamseddin and Barrett. 
At all times, patient confidentiality was respected and protected as per Human 
Investigations Committee's (HIC) rules and protocol. Patients' data was not stored with 
identifiers attached. Study code numbers were assigned. 
Study Population: 
All adult patients with end stage renal disease (ESRD) receiving heparin anticoagulation 
during their chronic hemodialysis at established heparin doses at the Waterford Hospital, 
in St. John's, Newfoundland and Labrador, in Canada were enrolled in this study. None 
of them had contraindication to heparin nor had expected kidney function recovery within 
six months of the time of enrollment. Patients not receiving heparin for any reason were 
excluded. 
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Study protocol: 
During the first four months of the study (Phase 1), heparin was administered as per our 
usual practice and doses were expected to be adjusted depending on the monthly routine 
ACT values by the Nephrologist covering our hemodialysis unit as per our protocols 
(Appendix A & B). During the second four months of the trial (Phase II), there was no 
ACT -guided heparin monitoring; unless clotting or bleeding occurred; and heparin was 
delivered at a fixed dose similar to the last bolus and maintenance doses delivered at the 
last HD session at the end of the first four months. If clotting or bleeding events occurred 
at any point during the second 4 months, heparin doses were expected to be adjusted by 
the Nephrologist covering the hemodialysis unit depending on a stat or a scheduled ACT 
value as per our protocols (Appendix A & B). 
Patients acted as their own controls and we tried to minimize the confounding factors 
during the period of the study by using whenever possible the same dialysis prescription 
throughout. Furthermore, since a few patients did not finish the study, as they were 
transplanted, transferred to different centers, or died before the end of the study, those 
patients did not have the full study length of exposure (exposure time) . Consequently, 
those patients could affect the study event rates over time. So, to accommodate for the 
primary events occurring during a particular length of observation, divided by time of 
16 
exposure, Poisson regression with offset variable analysis was used to calculate event 
rates as events per unit time, allowing the observation window to vary for each time unit. 
Prior to the entry in the study, the last available monthly work up results including 
complete blood count (CBC), ACT, serum electrolytes, creatinine, urea, urea reduction 
ratio (URR), calcium, albumin, phosphate and liver function tests were collected as a 
baseline. During the study routine monthly work up including the above tests were 
recorded as per our dialysis unit protocol. Baseline and regular coagulation profiles (PT 
and INR) were also collected for those patients receiving warfarin (Coumadin). Extra 
blood work up was ordered and followed up only as clinically indicated. 
Primary endpoints: 
1. Dialyzer clotting; defined as any of the following: 
The scale was based on visual inspection of the dialyzer and blood lines during and at the 
end of each session. The severity of the clotting event was classified as: 
1. Visible signs of clot or fibrin formation in the bottom of the dialyzer 
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2. Coagulated filter 
3. Circuit change required due to clotting 
2. Bleeding; defined as any of the following; 
1. Overt bleeding documented by clinical examination within 4 hours 
from hemodialysis session 
2. Overt bleeding documented by diagnostic investigations within 4 hours 
from hemodialysis session 
3. Doubling or more in the fistula needle site homeostasis time in patients 
with A VF; not secondary to fistula-related issues (No stenosis or high 
pressure) 
4. Unexplained fall in hemoglobin 2: 20 g/L within a month 
5. Requirement for blood (PRBCs) transfusion due to bleed 
Secondary endpoints: 
1. Urea clearance; measured by monthly urea reduction ratio (URR) 
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Study Data 
As a part of a routine intra- and post-hemodialysis evaluation carried out at each 
hemodialysis session by our hemodialysis nurses, the study primary endpoints including 
clotting and bleeding events, were reported by our dialysis nurses in details , recorded, and 
stored in our unit and hospital computer (MEDitech) system. Patient's paper and 
computer charts including Emergency Room (ER) records were also reviewed by Dr. 
Shamseddin to document those events that might happen either in our dialysis unit or later 
during ER visits or hospital admissions during the period of our study (8 months) with 
special attention given to the association between the occurrence of the clotting or 
bleeding event and the hemodialysis session initiation. Secondary endpoints as well as 
other laboratory parameters were obtained and collected completely by Dr. Shamseddin, 
from our monthly routine blood work up recorded in our MEDitech computer system. 
Dialysis machine pressure alarms and values, which were automatically downloaded to 
the MEDitech system, as well as all other relevant patients ' data were also reviewed and 
collected by Dr. Shamseddin. 
Primary endpoints events (clotting and bleeding) were reported as dichotomous 
dependent variables during the first and the second phases of the study. Event was 
reported as occurred or did not occur (Occurred = Yes = 1, Did not occur = No = 0). 
Furthermore, events were categorized further depending on the severity of the event using 
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a predefined scoring scale (Please refer to primary endpoints), and were reported as 
polychotomous or dummy dependent variables, when options included more than two 
possibilities. Secondary endpoint parameters including urea reduction ratio and 
hemoglobin were reported as continuous variables. The date of the last follow up, since 
some patients were transplanted, transferred to other hemodialysis units, or died, were 
reported as date variables. 
Other patients' data including demographic characteristics such as age, hemoglobin 
levels, and urea reduction ratio (URR) were reported as continuous variables while 
gender, etiology of end stage renal disease, co-morbidities, and the administration of anti-
platelet drugs, anticoagulation drugs, and heparin were reported as dichotomous and 
polychotomous variables when options included more than two possibilities. Data related 
to whether heparin was used or not, whether the dose was changed post events or not, 
whether the dose was effective in reaching therapeutic target or not, were reported as 
dichotomous variables. 
Data was saved encrypted in Microsoft® Excel® sheet and was stored without identifiers 
attached. Study code numbers were assigned and patient confidentiality was respected 
and protected as per Human Investigations Conm1ittee's (HIC) rules and protocol. A 
copy of above data was only available to Drs. Barrett and Shamseddin. 
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At the end of the study, data was analyzed by Dr. Shamseddin using IBM® SPSS 
Statistics version 20. Since patients acted as their own controls in the second phase and 
as primary endpoints were dichotomous variables, results were analyzed using two paired 
groups statistical tests including; paired t test, a McNemar test, logistic regression, and 
Poisson regression as appropriate, to compare the safety, clotting, and bleeding incidence 
rates between the monthly ACT-guided heparin (Phase I) and no routine ACT periods 
(Phase II). Poisson regression was used to compare the differences between the counts of 
clotting, bleeding, and the number of heparin dose changes between phase I and II. To 
compensate for any intrapersonal factors affecting the occurrence of any clotting or 
bleeding events, Logistic regression was used to compare between events whether they 
occurred or not, regardless the count of events. 
Further analyses were used to compare between different types of clotting and bleeding 
events that occurred during phase I and II. Effective heparin dose changes achieving 
ACT target after clotting and bleeding events were also compared between phase I and II. 
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Sam le size estimation: 
On average over 100 patients each receive three hemodialysis sessions per week in our 
dialysis unit. Prior to this evaluation, we completed a retrospective review of a sample of 
records under the then current monthly ACT -guided heparin monitoring protocol to 
estimate the number of bleeding and clotting events we might expect. We found two 
clotting events in a 20-patient sample over a 6-month period; both events required 
dialyzer and circuit change (2 clotting events per 20 patients per 6 months). So, over a 3-
month period, and in a 1 00-patient sample instead of 20 patients, we expected a total of 5 
clotting events. Now, in the absence of data and in order to plan our study, we assumed 
that bleeding events would occur at the same rate as clotting events, although the 
assumption was unfounded. Consequently and in the absence of any intrapersonal risk 
factors for bleeding or clotting events; the total clotting and bleeding events in a 100-
patient sample over a 3-month period would be 10 events or in other words 10% of 
patients might develop a clotting or bleeding event. 
As the relevant risk of bleeding or clotting is linked in time to dialysis treatments, we 
could convert this expected event rate to 10 per 3600 dialysis sessions ( 100 patients * 36 
dialysis sessions each in three months). We recognized that this event rate might be an 
underestimate, as staff was likely not routinely recording all relevant events in the charts 
in the past. 
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Since the purpose of this study was to ensure that our change in practice was not unsafe, 
we considered an increase in the overall bleeding and clotting event rate of 10/3600 
dialyses to be too large to justify not routinely monitoring the ACT. Depending on 
above, a sample size of 3600 dialysis treatments or in other words 100 patients on chronic 
hemodialysis three times weekly followed over three months, would yield a 95% 
confidence interval width of0.02-0.04% around such a difference in rates. This level of 
precision was judged sufficient for the proposed evaluation. Furthermore, and in order to 
achieve enough events during this evaluation, we extended the observation period to four 
months, before and after changing our current practice from the monthly monitoring of 
ACTs to that of measuring ACTs for clinical indications only. 
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RESULTS 
After obtaining the approval of the Human Investigations Committee and the Research 
Proposals Approval Conm1ittee of Eastern Health, 109 ambulatory adult patients with end 
stage renal disease (ESRD) receiving heparin anticoagulation during their chronic 
hemodialysis (HD) at established doses of heparin at the Waterford Hospital were 
enrolled in our study on August 01 , 2009. 
sis: 
Table J shows the results of the demographics and baseline characteristics of all patients. 
The average age of enrolled patients was 61.4 ± 15.9 years and 59% of participants were 
males (Tabk I ). Diabetes, hypertension, and glomerulonephritis were the most common 
etiologies of ESRD similar to other hemodialysis populations in North America (Tnblc 1). 
Hypertension and other comorbidities such as Diabetes, coronary artery disease, and 
peripheral vascular disease were associated with ESRD in 82%, 44%, 40%, and 31 % of 
patients, respectively (Table I). Only one third of patients had arteriovenous fistula 
(AVF) while the other 70% had hemodialysis line (Table I). Less than 50% of 
participants were receiving chronic Aspirin (43%) while very few were on clopidogrel 
(Plavix) and warfarin (Coumadin), 14% and 6%, respectively (Table I). 
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·- -Table 1: Patient's Demographic Characteristics 
N= 109 l Mean± SO 
Age (Year) 61.40 ± 15.99 
Gender- Male(%) 64 {59%) 
- ·-Etiology of ESRD (%) 
Unknown 7 {6.4%) 
DM 33 (30.2%) 
. 
HTN 12 (11%) 
GN 18 (16.5%) 
PCKD 7 (6.4%) 
Vasculitis 3 (2.8%} 
Renovascular 14 {12.8%) 
RCC 3 (2.8%) 
Other 12 {11%) 
Comorbidities 
DM 44% 
HTN 82% 
Cancer 22% 
CAD 40% 
PVD 31% 
-- 1-- ·-
HD Access - CVC 76 (70%) 
HD Access - AVF 33 (30%) 
ASA 43% 
Plavix 14% 
Coumadin 6% 
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Table 2 shows the reasons for loss to follow up and the number of follow up months of all 
patients who did not finish the study. Four patients received kidney transplantation while 
the other six patients died prior to the end of the study. The mean follow up during phase 
I was 3.82 ± 0.76 months compared with 3.7 ± 1.0 during phase II. 
·---- --
Table 2: Loss of Follow Up and Mean Follow Up 
Patient loss of Follow up Etiology Number of Follow up Months 
~ 
4 Kidney Transplantation 2 
10 Kidney Transplantation 4 
49 Death 6 
58 Death 5 
-62 Death 4 
64 Death 2 
80 Death 2 
84 Death 5 
91 Kidney Transplantation 7 
106 Kidney Transplantation 3 
·-
Mean Follow Up of All Patients- Months (mean±SD) 
Phase I 3.82 ± 0.76 
Phase II 3.7 ± 1.0 
During the first four months of our study (Phase I; August- November 2009), monthly 
routine ACTs were done as a part of our current practice and heparin doses were expected 
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to be adjusted by the Nephrologist covering our hemodialysis unit to achieve an ACT 
target of 150-200, as per our protocol (Appendix !\ & B). ACTs were expected to be 
rechecked after each heparin dose change to achieve above ACT target as per our 
protocol (Appendix !\ & B). 
During phase I, more than 50% of routine ACTs were below target (ACT < 150), 
however, heparin doses were changed only in < 10% of cases in general (Table 3, figure 
I ). 
Table 3: Routine Monthly ACT and Heparin Dose Changes 
Count l N l Routine 1 Heparin I • [ Post Hepann Change ACT 
(%) ! • Changed ·- - - - --,..-·-- --t ACT <150 I > 150 <150 Unknown 
Month 1 109 63 35 18 7 8 
(57.8%) (55.56%) (51.43%) (20%) (22.9%) 
Month2 108 63 2 0 0 0 
(58.33%) {3.17%) 
-
Month 3 105 54 6 3 2 1 
(51.43%) (11.11%) (SO%) (33.37%) (16.67%) 
Month4 104 51 4 3 1 0 
(49.04%) (7.84%) (75%) (25%) 
Furthermore, in cases where ACTs were low and heparin doses were changed, an 
effective ACT target > 150 was only attained in 50% of cases (Tobie 3. Figure I ). During 
c.__ _______________________ ----
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the first month of the study, more than half of the ACT values (57.8%) were below a 
target of ACT > 150 (Table 3). Heparin doses during that specific month were adjusted 
in 55.56% of cases, however, dose changes were effective, achieving a target ACT of > 
150, only in 51.43% of cases (Table 3), while 20% of cases failed to achieve ACT target 
> 150, or ACTs were never rechecked after changing heparin doses (23% of cases). 
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Figure 1: Subtherapeutic Routine ACT and Heparin Dose Changes during Phase l 
The above findings showed that routine monthly ACT-directed heparin dose adjustment 
and monitoring in chronic HD patients was not very consistent. However, as practiced 
locally, this could be due to the Nephrologist's response to the ACTs. 
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Clotting event was clearly defined and classified based on visual inspection of the 
dialyzer and hemodialysis circuit lines, to be done routinely by the HD nurse during and 
at the end of each HD session. The severity of each clotting event was evaluated by the 
HD nurse and scaled as defined above as 1, 2, or 3 (Please see primary endpoints), then 
was recorded regularly by our HD nurses in the patient electronic chart using our hospital 
computer (MEDitech) system at the end of each HD session as a part of a routine 
assessment to be done by our HD nurses during and at the end our each HD session. The 
above protocol secured detecting, capturing, and saving all clotting events, including 
minor clotting events, into our MEDitech system without missing any clotting-related 
data. 
There was a total of 87 clotting events during phase I compared with only 58 clotting 
events during phase II. 
Table 4: Clotting Events During Phase I & II 
Clotting Type 
Phase I 
Phase II 
1 
62 
41 
2 
23 
16 
3 1 Total Events 
2 87 
1 58 
Those events were further categorized depending on the clotting type (Table 4. Figure 2). 
All clotting types occurred more often during phase I compared with phase II (Table 4). 
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Clotting Event Counts • Phase I Phase II 
Figure 2: Clotting Event Counts 
The heparin dose was changed following only one third (29/87) of all clotting events 
during phase L Furthermore, heparin dose change was effective in achieving an ACT 
target of > 150 only in 19 events out of these 29 cases (Table 5). 
--Table 5: Total Clotting Events and Heparin Dose Changes 
-
Total Heparin changed Effective Change 
I ' (%) (ACT> 150) 
r---
-- -------Phase I 87 29 (33.3) 19 (65.5) 
Phase II 58 3 (5) 1 
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Alternatively, heparin dose was changed following only 5% of all clotting events that 
occurred during phase II and heparin dose change was effective, achieving ACT target of 
> 150 after changing heparin dose, in only 1 ofthose 3 cases (Table 5). 
Since clotting events type 2 and 3, compared with type 1, were more clinically important 
as serious clinical complications of clotting, we further categorized clotting events during 
phase I and II, to either type 1 events or type 2 and/or 3 events. Subsequently, we 
compared events occurrence, heparin dose changes after clotting occurrence, and whether 
heparin dose change was effective in achieving an ACT target > 150 post heparin dose 
change (Table 6). 
The data show that the heparin dose was changed more often and the dose change was 
more effective during phase I compared with phase II (Table 6). Heparin dose was 
changed after clotting events in almost one third of all type 1 clotting events and in 40% 
of all type 2 and 3 clotting events during phase I (Table 6 ). Furthermore, heparin dose 
change was more effective, achieving an ACT target > 150 post heparin dose change, 
during phase I compared with phase II, especially after clotting events type 2 and 3 (Table 
6). 
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-
Table 6: Clotting Event Types and Heparin Dose Changes 
Clotting Events during Phase I 
Total Heparin changed Effective Change 
(%) (%) 
·-
Type! 62 19 (30.6) 12 (63.2) 
-
Type 2 or 3 25 10 (40) 7 (70) 
-· Clotting Events during Phase II 
,-
Total Heparin changed Effective Change 
(%) (%) 
Type! 41 1 (2.4%) 0 
- -- ---Type 2 or 3 17 2 (12%) 1 
On the other hand, bleeding event was clearly defined and scaled as defined above as 1, 
2, 3, 4, or 5 (Please see primary endpoints). However, due to the nature and definition of 
bleeding events, which could occur at any point within the fust 4 hours from HD session 
initiation up until a month post HD session, detecting and capturing all bleeding events 
was much harder compared with clotting events which were noted and recorded routinely 
as mentioned above in our hospital computer (MEDitech) system. Patient's electronic 
and paper records were reviewed by Dr. Shamseddin to identify any bleeding events prior 
to saving those events encrypted in a Microsoft® Excel® sheet. Consequently, although 
missing bleeding-related data could not be completely averted, we believe that little data 
were missed. However, if further studies were required in the future, the definition of 
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bleeding events and the methods of capturing and recording bleeding events has to be 
respecified to avoid missing any data. 
There was a total of 28 bleeding events during phase I compared with 32 bleeding events 
during phase II (T::~blc 7). Those bleeding events were further categorized depending on a 
pre-defined scoring system into 1 to 5 bleeding types (Table 7). 
Table 7: Bleeding Events During Phase I & II 
Bleeding 1 2 3 4 ls I Total Type 
I '. 
Phase I 2 0 14 6 6 28 
Phase II 0 0 20 9 3 32 
Bleeding events type 1 (Defined as overt bleeding documented by clinical examination 
within 4 hours from hemodialysis session) were identified only in two cases during phase 
I (Table 7). While type 2 bleeding events (Defined as overt bleeding documented by 
diagnostic investigations within 4 hours from hemodialysis session) were not identified in 
any cases in either phase (Table 7). Bleeding events type 3, 4, and 5 (Please refer to 
primary endpoints), occurred more often in both phases at different rates (Table 7). 
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Heparin doses were not frequently changed after bleeding events, as you might have been 
expected (Table g). Out of all bleeding events during phase I, heparin doses were 
changed only after 4 bleeding events. However, dose changes were effective, achieving a 
target ACT of 150 to 200 post heparin dose change, in all cases (Table g). Moreover, 
heparin dose was changed only after three bleeding events occurred during phase II 
(Table~). However, since ACTs were not remeasured after heparin dose changes 
following those bleeding events in phase II, heparin dose changes could not be evaluated 
as to whether they were effective, achieving a target ACT of 150 to 200, or not (Table g). 
Table 8: Bleeding Events and Heparin Dose Changes 
All Bleeding Events Heparin Changed Effective Change 
(%) ACT> 150 (%) 
Phase I 28 4(14%) 4 (100%) 
- -Phase II 32 3 (9%) ~Available ACT 
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Comparative Analysis: 
Clotting Events: 
To identify whether the difference between the counts of clotting events occurring during 
phase I and II was statistically significant, and since clotting event counts have the 
Poisson distribution (36), we analyzed our study data using Poisson Regression (37. 
38). Poisson distribution is a discrete probability distribution that expresses the 
probability of a given number of events occurring in a fixed interval oftime, ifthese 
events occur with a known average rate and independently of the time since the last event 
(36). Poisson Regression is a fom1 of regression analysis used for independent count 
data model (37. 38), which assumes that: 
1. The dependent variable (Y = clotting event) has a Poisson distribution 
2. The dependent variable is a count of independent events over time at risk 
3. The logarithm of its expected value can be modeled by a linear combination of 
unknown parameters 
Furthermore, the Poisson regression model rate (A. = count of event/number of times event 
could have occurred), estimates the risk of the event occurring in a specific group of 
people during a specified period of time, known as exposure time (3~). However, when 
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the study duration is long enough and not all subjects are observed for the same length of 
time (such as if patients were lost to follow up, died, or transferred out of the study); the 
risk of the event can be presented in Poisson regression as incident rate ratio (IRR) for 
the reference group (3~ . 39). Those incident rate ratios (IRRs) can be reported by the 
IBM® SPSS Statistics version 20 outputs (38, 39). IRRs are equal to the coefficients 
above exponentiated from the IBM® SPSS Statistics version 20 outputs (3~, 39). 
Using this approach, the incident rate for all clotting events that occurred during phase I 
was significantly higher (1.5 times) than that during phase II (Table 9, IRR 1.5; 95% CI: 
1.08 - 1.09, p = 0.0 17). 
Table 9: Total Clotting Events per Phase (Poisson Regression) 
Parame1er Estimates 
9 5~ Wald Conficlence Interval 
95 '1<· Wald Confidence Interval Hypothesis Test for Exp(Bl 
Wald Chi-
Porometer 8 Std. Error Lower Upper Square df Sig. [Xpi8) Lower Upper 
Ontercepil - .63 1 . 1313 -.888 - .3 74 23 .086 I .000 .5 32 .411 688 
(Phase• ! J .405 . 1695 .073 .738 s. 721 I .017 1.500 1.076 2 .091 
(Phasea 2J o• l 
IS<:alel I b 
Oependem variable Totai_Cioung_Event 
Model. {Intercept), Phase 
a. Set to zero because this parameter is redundant. 
b. Fixed ar the displayed value. 
Furthermore, when we compared the counts of different types of clotting events that 
occurred during phase I and phase II, we found that all types of clotting events occurred 
surprisingly more often during phase I compared with phase II (Table l 0, ll , 12); type 1 
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(1.5 X), type 2 (1.44 X), and type 3 (2 X). However, the incident rate ratio of clotting 
events type 1 was the only statistically significant rate (P = 0.04), while the incident rate 
ratio of clotting events type 2 (P = 0.27), and 3 (P = 0.57) were not statistically 
significant (Table I 0. ll. J 2). 
Table 10: Total Clotting Type 1 per Phase (Poisson Regression) 
Parameter Estimates 
9 5% Wald Confldern:e Interval 
95% Wald Confidence lmerval Hypothesis T e" for [X0(8) 
Wald Chi-
Parameter 8 Std. Error Lower Upper Square df Siq. ExpiBI LOWH Up pH 
llntrrceoo - .978 IS62 - 1.284 . . 672 39 198 I 000 .376 .277 .511 
[Phase = II .414 .2013 .019 .808 4.221 I .040 1.512 1.0 19 2 .2• 4 
{Phase•21 o• I 
!Scale I I b 
Dependent Variable Totai_Ciotting_Type_One 
Model: llnterceptl. Phase 
a Set to zero betatJ'it th1s parameter is redundant. 
b. Fixed at the displayed value. 
Table 11: Total Clotting Type 2 per Phase (Poisson Regression) 
Par~;meter Estimates 
95% Wald Confidence Interval 
95!1> Wald Confidence Interval Hypothesis Test for ExoiBI 
Wald Chi-
ParamPtPr B Std. Error Lower Upper Square df Sig. Exp!Bl Lower Upper 
flntercepO - 1.919 .2500 - 2.409 - 1.4 29 53.906 I .000 . I4 7 .090 .240 
[Phase a II .363 .3255 - .275 1.001 1.24 3 I .265 1.438 . 759 2.721 
[Phase • 21 o• I 
IS< aiel l b 
Dependent Vanable rotal_clotung_ Type_ Two 
Model llnte rceon. Phase 
a. Set to zero because this parameter IS redundant. 
b. Rxed at the displayed value. 
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Table 12: Total Clotting Type 3 per Phase (Poisson Regression) 
Paro.merer Estimates 
95% Wald Confidence Interval 
95 '>!. Wald Confidence Inte rval Hypothesis Test lor Exp(Bl 
Wald Chi-
P3rameter 8 Std. Error LO\Wr Upper SQuare df S1g. Exp£81 LOWef Upper 
llnterceptl - 4 .691 !.0000 -6.651 -2 711 22 009 1 .000 009 00 1 .06 5 
[Phase• ! ) .693 1.2247 -1.707 3.094 .320 I .S 71 2.000 .151 2l .OS6 
[Phase= 21 o• l 
(Scale) I b 
Dependent Variable rotai_Ciotting_Typc_Three 
Model. Unte1 ceptJ. Phase 
a. Set to zero be(JU5e thi~ P.lrametl!r IS redundJnt 
b FIXPd at th• displ.wed v.liue . 
In our study, a few patients did not finish the study, as they either had a kidney transplant 
(x 4 patients) or they died (x 6 patients) before the end of the study (Table 2). 
Since the above 10 patients did not have the full study length of exposure (exposure time), 
those patients may consequently model clotting event rates in this study over time and 
fa lsely underestimate or overestimate results (-tO). So, to accommodate for the clotting 
events occurring during any particular length of observation during the study, divided by 
the time of exposure, Poisson regression with offset variable analysis was used to 
calculate clotting event rates as events per unit time, allowing the observation window to 
vary for each time unit ( 40). 
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Table 2: Loss of Follow Up and Mean Follow Up 
Patient loss of Follow up Etiology ·1 Number of Follow up Months 
~ 
4 Kidney Transplantation 2 
10 Kidney Transplantation 4 
49 Death 6 
-58 Death 5 
-62 Death 4 
64 Death 2 
80 Death 2 
84 Death 5 
91 Kidney Transplantation 7 
106 Kidney Transplantation 3 
Mean Follow Up of All Patients- Months (mean± SO) 
Phase I 3.82 ± 0.76 
Phase II 3.7 ± 1.0 
Using offset variable analysis, the incident rate ratio for all clotting events during phase I 
remained unexpectedly higher ( 1.41 times) than that during phase II and was statistically 
significant (Table 13, IRR 1.41 ; 95% CI: 1.01-1.97, P = 0.041). 
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Table 13: Total Clotting Events per .Phase (Poisson Regression- offset Variable) 
9Sl!. WJid Confldell<t lnttr>Jal 
Par>mtlfr 8 !Kd. (rrO< lower 
UnteiCtPO - 4 ~·z .IJB 
- · 799 
IPhJso• l} . l46 .169S .014 
(Piu>e • 2} o' 
IScalt l t • 
Otptr>dem v~n~ble f01a1 tlo~l1<) t vent 
Mod•l l lntooctp , Phast . <>ltlt l • Moolhs _or_ru 
.1 SC'::t to lfJO bN,\ui!Jt lh1~ p.trdtntl r IS r tdund~H~t 
b. ft•ed attht dlspla'(td value. 
Uppor 
- 4 284 
.679 
ll;oorhtlo! l r~t ! 
W~kllh.l 
Squ.,. df Soq. Expl ! l 
1196 44 7 l 000 0 11 
• 177 I 041 I 414 
I 
<))'Vi 1\'~1<1 ~onftdtn<~ Intent> I 
f()f [J<p (8l 
lOWI!t Uppor 
008 0 14 
1 014 1.971 
All types of clotting events occurred more often during phase I compared with phase II 
(T3blc 14, 15, 16), type 1 (1.43 X), type 2 (1.36 X), and type 3 (1.89 X). However, none 
of the incident rates of clotting event types were statistically significant (Table 14_ 15. 
16 ), type 1 (P = 0.08), type 2 (P = 0.35), and type 3 (P = 0.61 ). 
Table 14: Total Clotting Events Type 1 per Phase (Poisson Regression- Offset Variable) 
Paramet@r Estimates 
95% W,lld ConfodenCf lnltrval Hypothesi' 1 til 
Pardrneter B Std. Error LO\o..•er 
(Inte rce pt) - 4.889 . l S6l - 5 195 
!Phase• I I .3 55 .2013 -.040 
!Phase: ZJ o• 
!Scale) I b 
Dependent Varoable Totai_Ciottonq_Type_Dne 
Model (lnttrcept), Phase. offset ; Months_of_FU 
a. Set to zero because th1s parameter is redlmdant. 
b. Fixed at the displayed value. 
Wald Cho-
Uppe r Square dl 
- 4.583 979.883 I 
.7 49 3.102 I 
9S% Wald Confidence Interval 
for ExpiBI 
Sig. Exp(Bl Lower Upper 
.000 008 006 .010 
.078 1.426 .9!;1 z .11 5 
I 
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Table 15: Total Clotting Events Type 2 per Phase (Poisson Regression- Offset Variable) 
Parameter Estimates 
9Sllt Wald Confidence lnterv.ll Hypothem ft\1 
Pdrameter 8 Std £rror LO\ver 
(Intercept) - 5.810 2500 - 6 .320 
(Phdse• l l .]04 . J2S5 -.334 
(Phdse•2 1 o• 
(Scale I 1" 
Dependent Va11able Tot•l_clortlnq_Type_Two 
Model (Intercept). Phase. offset~ Months_of_FU 
a.. Set to .t:eso because thtS p;uameter is redunddrll. 
b . FIXed at the displayed value. 
Wald Chi-
Upper Square df 
-5 Ho SH 767 I 
.942 .871 I 
9S'I\ \Vald Confidence Interval 
lor (Xp(81 
S•g £xp(Bl LO\.ver Upper 
000 OOJ OOl oos 
lSI 1.]55 .716 2 .565 
I 
Table 16: Total Clotting Events Type 3 per Phase (Poisson Regression- Offset Variable) 
Paramf!ter Est im ates 
95% Wald Confidence Interval Hypothesis Test 
Parameter 8 Std. Error LO\Ver 
(Inte rce pt) 
-8 .602 1.0000 - 10.562 
(Phase= 11 .634 1.2 24 7 -1.766 
(Phdse = 21 o• 
!Scale I 1 b 
Dependent Vanable Totai_Ciotllng_Type_Three 
Model !Intercept). Phase. offset a Months_ot_FU 
a. Set to zero because this parameter IS redundant. 
b F1xed .11 the displayed value. 
Wald ctu-
Upper Square d( 
-6 .6~2 73 .999 I 
3.035 .268 I 
95~, Wald Confidence Interval 
for EXpiBI 
Sig. [Xp(BI Lower Upper 
.000 .000 .000 .001 
.60S 1.885 . 171 20.792 
I 
While clotting events did not occur in some patients, clotting occurred more often in 
specific patients than others due to theoretical intrapersonal diathesis. However, the risk 
of clotting in those patients with higher clotting event counts, was not affecting outcomes 
over a short period of time, since events in those patients occurred at different intervals. 
Sometime, two events occurred in a row, then no event occurred for a variable length of 
time, followed by another event, for example. 
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In the setting of above findings and since the occurrence of clotting event is a dependent 
categorical variable (Clotting occurred; Yes= 1 or No= 0), to evaluate intrapersonal 
effects on clotting events, we compare the risk of any clotting occurrence versus not 
occurring between phase I and II, using binary Logistic regression. Binarv Logistic 
Regression is a type of regression analysis used for predicting the outcome of a 
categorical dependent variable based on one or more predictor variables. It measures the 
relationship between a categorical dependent variable and usually a continuous or 
categorical independent variable (or several), by converting the dependent variable to 
probability scores and providing the odds ratio (Exp (B)) for each of the dependent 
variables ( 4 1 A2). 
An odds ratio (OR) measures the association between an exposure and an outcome and 
represents the odds that an outcome will occur given a particular exposure, compared to 
the odds of the outcome happening in the absence ofthe same exposure (4:2,43). Odds 
ratios compare the relative odds of the occurrence of the outcome of interest (e.g. clotting 
or bleeding events), given exposure to the variable of interest (e.g. exposure to monitored 
heparin on hemodialysis versus exposure to unmonitored heparin on hemodialysis). The 
odds ratio (OR) can also detem1ine whether a particular exposure (e.g. exposure to 
monitored heparin on hemodialysis versz.1s exposure to unmonitored heparin on 
hemodialysis), is a risk factor for a particular outcome (e.g. clotting or bleeding events), 
and compares the implication of various risk factors for that outcome (-B). 
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OR= 1 
OR > 1 
OR < 1 
Exposure does not affect odds of outcome 
Exposure associated with higher odds of outcome 
Exposure associated with lower odds of outcome 
When a logistic regression is calculated, the regression coefficient (B) is the estimated 
increase in the log odds of the outcome per unit increase in the value of the exposure 
(-B). In other words, the exponential function of the regression coefficient [Exp (B)] is 
the odds ratio associated with a one-unit increase in the exposure (42,43). The 95% 
confidence interval (CI) estimates the precision of the OR. A wide CI indicates a low 
level of precision of the OR, whereas a narrow CI indicates a higher precision of the OR 
( 43). The 95% CI is often used as an alternate for the presence of statistical significance 
if it does not overlap the null (e.g. OR = 1) value ( 43 ). Otherwise, it would be unsuitable 
to explain an OR with 95% CI that crosses the null value as indicating evidence for lack 
of association between the exposure and outcome ( 4_, ). 
The Odds Ratio (OR) of any clotting event phase I was significantly higher (OR = 1.87) 
compared with phase II (Table 17, OR = Exp (B) 1.87; 95% CI: 1.03-3.39, P = 0 .04). 
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Table 17: Any Clotting per Patient per Phase (Binary Logistic Regression) 
Parameter Estimottes 
9S"f.> Wald Conr,dence Interval 
9S% Wald Confidence Interval Hypothesis Telt for ExpiBI 
Wald Cho-
Par. meter B S.td. Error LO\ver Upper Square df Sog. ExpfBI Lmv~r Upper 
llntfr<epU - 1.212 .2278 - J.6S8 
(Phase• II .627 .3030 .033 
(Phase• 21 o• 
ISUiel 1 b 
Dependent Variable. Any_Ciottong_per_Pauent_per- Phase 
Model (lnt•rceptl. Phase 
a. Set to uro because th1s pilrilmetr-r is redund.lnt 
b Fixed at the d isplayed value 
- .76S 28.298 I .000 .298 . 190 
1.221 4.281 I .039 1.872 1.034 
1 
Given on the above findings and since the majority of patients finished the study, we 
concluded that both the incident rate ratio and the Odds ratio of any clotting event in 
.465 
3 .390 
phase I was significantly higher than those in phase II. These findings were surprisingly 
unexpected, as prior to this study, we expected more events to occur in phase II since 
heparin doses were not monitored and adjusted appropriately during this phase compared 
with phase I. To verify whether the higher incident rate and risk of clotting events 
observed during phase I was due to a misplaced comfort on the part of the Nephrologists 
that the heparin dose was routinely monitored as well as the less than expected response 
of the Nephrologists to change heparin dose and to follow up on ACT results to adjust 
heparin doses appropriately, we compared whether heparin dose was changed more often 
in phase I versus phase II, using Poisson regression without and with offset variable 
analysis (since 10 patients left the study before the end of the study as mentioned above). 
Heparin dose was changed following 29 clotting events out of 87 events that occurred in 
phase I compared to 3/58 events in phase II (Table 5). 
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·---Table 5: Total Clotting Events and Heparin Dose Changes 
l Total I Heparin changed : Effective Change 
I 
• {%) 1 (ACT> 150) 
Phase I 87 29 (33.3) 19 (65.5) 
Phase II 58 3 (5) 1 
-
As expected, heparin doses were changed significantly more often (9 X) when clotting 
occurred in phase I compared with phase II (Table 18, IRR 9.67; 95% CI: 2.95-31.73, P = 
0.000), even when we evaluated our data using offset variable analysis since 10 patients 
left the study before the end of the study (1 able 1 Y, IRR 9.11 ; 95% CI: 2.78-29.92, P = 
0.000). 
Table 18: Incident Rate Ratio of Heparin Dose Change Post Clotting Events (Poisson Regression) 
Parameter Estimates 
95% Wald Confidence Interval 
Paran>PtPr B Std. Error lower Upper 
(lntorcepO - 3.593 .5 774 - 4 .7l4 
[Phase~ I I 2.2 69 .606 5 1.080 
1Phase: 2J o• 
!Scale! I h 
Dependtmt Variable totalc lotungonhepann_heparlnChanged 
Model Omerceptl. Phase 
a. Sec to zero btcause th1s paramettr is redundant. 
b. Fixed ar rhe d"played va lue. 
2.46 1 
3.45 7 
HypotheSIS T e 5I 
Wald Chi-
Sq uare df 
38.723 l 
13.993 I 
95'1. Wald Confidence Interval 
for Exp!SJ 
S1g . £xpiSI Lower Upper 
.000 .028 .009 .085 
.000 9.667 2 .945 31.733 
I 
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Table 19: Incident Rate Ratio of Heparin Dose Change Post Clotting Events (Poisson Regression-
Offset Variable) 
Parameter Estimates 
95% Wald Confidence Interval 
Parameter g Std. Error Lower Upper 
!lntercepU - 7 .504 .5 77~ -8 635 - 6 3 72 
/Phase• I ] 1.110 .6065 1.021 3.395 
/Phase:2] o• 
lxale) 11> 
Dependent Varl.lble totalclottmgonl\eparln_l\epannChanged 
Model llntercepU. Phase. offset~ Months_of_FU 
a. Set to Lero because thl!t parameter 1s redundant. 
b. Rxed at the drsplayed value. 
ltypothe:sis fe.\t 
Wald Chr-
Square df 
168 9 16 l 
JJ .l7S l 
95~ Wald Confrdence Interval 
for EXPIBI 
Sig . ExptBl Lower Upper 
.000 001 000 .002 
.000 9.113 2.776 29.915 
I 
Furthermore, to compare whether heparin dose change was more effective (Defined as 
ACT value post heparin dose change achieved a target ACT > 150) in phase I versus 
phase II, we analyzed our data using Poisson regression without and with offset variable 
analysis. Heparin dose change was effective in 19 clotting events out of 29 events where 
heparin dose was changed in phase I compared with 1/3 cases in phase II (TJblc 5). 
Heparin dose change was significantly more effective when heparin changed in phase I 
compared with phase II (T<1blc 20, IRR 207.1; 95% CI: 27.73-1547.02, P =0.000), even 
with offset variable analysis (Table 2 1, IRR 189.45; 95% CI: 25.36-1415.2, P =0.000). 
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Table 20: Incident Rate Ratio of Effective Heparin Dose Change Post Clotting Events (Poisson 
Regression) 
Puameter htimoues 
95% Wald Conflden<:e Interval 
95% Wald Confld~n<~ Interval HypotheSI< Tost for Expf8l 
Wald l h•-
Par am• tor 8 Std. Error l ()\1\:ff Upper SQuar!' df Sig. Expi8) Lower Upper 
!Interce pt) -4.69 1 1.0000 -6 .65 1 - 2.731 22 .009 I .000 .009 .001 .065 
[Phase• l l UH 1.0260 3 .322 7.J4•\ l7.021 1 .000 l07 . 100 Z7.72 S 1547.015 
[Phase ; ZJ o• 1 
(Scalel l b 
Dependent Variable_ totaldottingonhepann_heparin hanged_Effecuve chanQe 
Model llntercepo. Phase 
a. ~t to zero because this param£ter IS redundant. 
b. Frxed .Jt the drsplayed valu~ . 
Table 21: Incident Rate Ratio of Effective Heparin Dose Change Post Clotting Events 
(Poisson Regression- Offset Variable) 
Parameter Estimates 
95"1 Wald Confid ence lnlorval l typothem Te<t 
Wald Chi-
P.uame lor 8 Std. Error Lower Upp~r Square 
UnterceptJ - 8 .602 1.0000 - 10 .562 -6.642 73.999 
[Phase• ll 5.244 1.0260 3 .233 7.255 26 .126 
[Phase &ll o• 
(Scaler I • 
Dependent Vanable total< lotllngonhepann_hepannChanged_ETfEl Tllllthange 
Model· !Intercept!. Phase. offset • Months_or_ru 
a.. Set to zero because thrs parameter rs redundant. 
b. Fixed •t the diSplayed value. 
df 
I 
I 
95'!1; Wald Confidence Interva l 
for ExptBl 
S•g. Expl81 Lower Upper 
.000 000 .000 .001 
.000 189.454 2'5.362 141 5.20l 
1 
To extend above findings into different types of clotting events, we repeated our analysis 
combining clotting events type 1 separately from type 2 and/or 3 events and we compared 
those findings between phase I and II (Table 6). There was 19 clotting events type 1 out 
of 62 events where heparin was changed in phase I and change was effective in 12/19 
events. While in phase II, heparin dose was changed only in 1 event out of 41 clotting 
events type 1 and change was not effective (Table 6). On the other hand, there were 10 
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clotting events type 2 or 3 out of 25 events where heparin was changed in phase I and 
change was effective in 7 I 10 events. In phase II, heparin dose was changed only in 2 
events out of 17 clotting events type 2 or 3 and change was effective only in 1/2 events 
(Table 6). 
Heparin dose was changed significantly more often when clotting events type 1 occurred 
in phase I compared with phase II, P = 0.04 (Table 22) and P = 0.005 (Table 23). 
Table 22: Incident Rate Ratio of Heparin Dose Change Post Clotting Events Type 1 (Poisson 
Regression) 
Parametu Estimates 
95% W,lld Confirltnce Interval 
Param•ter 8 >td. Error Lower Upper 
(Intercept) -4 .691 1.0000 -6.65 I - 2.73 1 
!Phase"' 11 2.944 1.0260 .934 ~ .9)) 
[Pha.e=ZI o• 
!Scale I l b 
Dependent Va11able tolalclomngonheparln_tYPe••_hepannLnanqed 
Model (Intercept). Phast 
.1. Se t to zero because this parameter is redundJnt. 
b. Fixed at the d isplayed value. 
llypoth.sls Test 
Wald Chi-
SQuare d f 
22 .009 1 
&.236 1 
95~ Wald Confidence lmerval 
for (Xp{81 
~lg. £xpi8J Lower Upper 
.000 .009 .001 .065 
.004 19.000 2.544 14!.928 
) 
Table 23: Incident Rate Ratio of Heparin Dose Change Post Clotting Events Type 1 
(Poisson Regression - Offset Variable) 
P~r011meter Est im.Jtes 
95:1\ Wald Confidence Interval 
Pilr.lmetrr 8 Sid. Error Lower Uppor 
(lntercepo -8.602 1.0000 - 10.562 -6.642 
[Phase• II 2.865 l.Ol60 .875 4.896 
[Phase• 21 o• 
(Scale) l b 
Dependent Vanable totalclomngonheparln_typeR•_hepannChanged 
Model (lnterceptl. Phase. offset # Months_of_ru 
a. Set to zero becauu th1s parameter is re.cfundant 
b. Flxed dt the displayed value. 
Hypothes•s Test 
Wald Chi-
Sq uare df 
73.999 1 
7.909 l 
9';'\\ Wald Confidence Interval 
for Expi BI 
Slg. Exp(81 Lower Upper 
.000 .000 .000 .001 
.005 l7.9ll 2.398 133.79 5 
l 
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The dose change was also significantly more effective when heparin changed in phase I 
compared with phase II, P = 0.000 (Table 2-l , 25). However, there were not enough 
clotting events during phase II where heparin was changed and none where the change 
was effective (Table 6), which could maximize the difference between phase II and I. 
Table 24: Incident Rate Ratio of effective Heparin Dose Change Post Clotting Events Type I (Poisson 
Regression) 
Patamettr Estimates 
9S" Wald Confid~nu Interval HypotheSIS T~Sl 
WJid Chi 
Panmore r B Std. (rror Lower Upper SQuare. 
omerceptJ - U.335 .l8Sl - 28.900 - Zl. lb9 9634 .264 
[Phasec l J 28.740' 
[Pha.e• ZI o• 
(S<:aleJ I ' 
DEpEndent Vanablo totalclottingonhopartn_<ypel !_heparmchange_EfrECTIVE 
Modo! llnterceptl. Phase 
df 
I 
>tq. ExpiB) 
.000 4 .94 8E - 013 
3.032[+ !2 
I 
a. HessiJn matrix singularity 1s caused by this parameter. The parameter estimate at the last ite ration 1s displayed. 
b. Set ro Jero bt!'C<HJ.Se rhis parameter is redundant. 
c. Fixed at the d1splayed value. 
qso;s Wald Confid~nce Interval 
for ExpiBl 
Lower Upp" 
l .SlOE- 013 8.71ZE- OJ3 
.000 .000 
Table 25: Incident Rate Ratio of effective Heparin Dose Change Post Clotting Events Type 1 (Poisson 
Regression- Offset Variable) 
Parameter Est imate s 
95:'6 Wald Confide nco lntotval Hypothesis Tt~t 
W•ld Chi-
Parrlmete r 8 Std. Error Lower Upper $Qllaf! 
Urnercepu - 31.335 .2837 - J 1.901 - 30.769 11782.683 
(Phase~ II 27. 741 ... 
{Phase•ZI o• 
IS<Oie) I ' 
D~ptnd~nt va ri.lble !OtalclotUngonhepa.rin_typt# '~heparinchange_£FFECTIV[ 
Model ilnl@.reeptl , Phase, offsf't • Months:_of_FU 
dl 
1 
~'9· [XpiBI 
.000 .000 
1.116[•11 
l 
.1 . Hess•an matrix slngui.Hitv Is caused by this paramuer. Th~ parameter estimate .u the IJst l(e ratlon is diSPlayed. 
b. Se t to 2ero because this parameter is redundant. 
c. Fixed at c.ht d1sptaye.d value 
9S% Wafd Confidence lntervJI 
for ExptBl 
Lower Upper 
.000 .000 
.000 .000 
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Moreover, heparin dose was changed significantly more often if clotting events type 2 or 
3 occurred in phase I compared with phase II, P = 0.04 (Table 26. 27), but the dose 
change was not significantly more effective when heparin changed in phase I compared 
with phase II, P = 0.43 (Table 2~, 29). 
Table 26: Incident Rate Ratio of Heparin Dose Change Post Clotting Events Type 2 or 3 {Poisson 
Regression) 
P.;uameter btimate.s 
95% Wald Contid~nce Interval 
Parameter g Std. Enor Lower Upper 
tlntercepO 3.998 .707 1 5.384 - 2.612 
IPhase ~ l l 1.609 .7746 .091 3.128 
1Phase~2J o• 
(Scale I t• 
Oepenuent vanable totalclotungonheparln_<ypePZor 3_heparrnchanged 
Model. llnterceptJ. Phase 
a. Set to zero because this parameter is redundant. 
b. roxed at the diSplayed value 
Hypothesis Test 
Wald Chi-
Square df 
31.971 1 
4.3 17 1 
95% Wald Confrdence Interval 
for Expr8) 
Srq. [Xp j81 LD~A-e r Upper 
000 .018 .005 .073 
.038 5.000 1.096 22.820 
I 
Table 27: Incident Rate Ratio of Heparin Dose Change Post Clotting Events Type 2 or 3 (Poisson 
Regression- Offset Variable) 
Parameter Es-timates 
9Sl!, Wald Confidence Interval 
Parameter g Std. Error Lower Uppor 
(Intercept) - 7.909 .7071 .. 9 .295 6.523 
1Phase~11 1.550 .7746 .032 3.069 
IPhase~21 o• 
(Scale! 1 b 
Dependent Variable totaldomnqonheparln_<ypeP1 or 3_hepar 111changM 
Model !Intercept), Phase . offset = Months_of_FU 
a . Set to Ler o because this pa rameter is Fedundant. 
b. Foxed at the drsplayed value. 
ftypothesrs Test 
Wald Ch•-
Square df 
125. 109 l 
4.006 l 
95% Wald Confidence Interval 
for Exp•SI 
5ig. [Xpl8) l~-er Uppor 
.000 .000 .000 .00 1 
.0 4 s 4.7 13 1.033 2l.S 12 
1 
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Table 28: Incident Rate Ratio of Effective Heparin Dose Change Post Clotting Events Type 2 or 3 
(Poisson Regression) 
Parameter [st imtltes 
95'>.'. Wald Confldtnce Interval HypothesiS Test 
wald Cht-
Par.l mPIPr 8 Std Error Lower Up pH SQuare 
!Intercept) - .693 1.0000 -2 .653 1.267 .480 
!Ph.lsc• l l .84 7 1.0690 - 1.24 8 2.94 3 .628 
1Ph.lso: 2 J o• 
!Scale I I " 
Dependent Vanable totalclo!ttngonheparln_type •lor J_lleparmchanged_HFElliVl 
Model (lnterceptl. Phase 
a. Set to zero be<a.use th1s parameter is redundant. 
b. Fixed at the d osp layed value. 
df 
1 
1 
9 s·~ Wald Co nfidence Interva l 
for Lxp!Sl 
5oq Exp!Rl lOWPf Uppe r 
.488 .500 .070 3. 550 
.4 28 2.333 .287 18.965 
I 
Table 29: Incident Rate Ratio of Effective Heparin Dose Change Post Clotting Events Type 2 or 3 
(Poisson Regression - Offset Variable) 
Parameter Estim..,tes 
95% Wald Coofodence trnerval Hyp01hesos T elt 
Wald Chi-
Par.l meter 8 Std. Error Lower Upper SQuare 
(Intercept) - 4 .693 1.0000 - 6 .653 - 2.7 3 3 22 .026 
!Ph.lse• ll .M7 1.0690 -1.248 2.943 .b28 
!Ph,.e~2l o• 
tScale) J " 
Dependent vanable. totalclottongoohepann_typelll or .l_heparoncha nged_EFFECTIVE 
Model fln te rceptl. Phase . offset ~ Months_of_FU 
a Set to zero because tht5 pMa metu 1s re.d undant 
b . Fiked a t the d isplayed value. 
df 
1 
1 
91% Wald Confidence Interval 
for ExpiBI 
~lg ( xp(RI LO\Ner Upper 
.000 .009 .00 1 .065 
.428 2.3 33 .287 18 .9bS 
I 
To measure the association between clotting events and heparin dose change during phase 
I and II as well as the association between heparin dose change and effective heparin 
change, we ran logistic regression analysis using any clotting event occurrence, regardless 
of the type or count of events, during phase I and II. The Odds ratio of changing heparin 
during phase I compared with phase II was OR = 6. 1; 95% CI: 1.72-2 1.52, P = 0.005 
(Table 30), and the OR of effective heparin dose change in phase I compared with phase 
II was significantly higher (Table 3 1, OR 180; P = 0.000). 
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Table 30: Odds Ratio of Heparin Dose Change if Any Clotting Occurred (Binary Logistic Regression) 
Parameter Estlmales 
95% Wald Conftdtnct Interval 
Parame te r 8 Std. Error LQY..-er Upper 
llntercepl) -3 .565 .5855 - 4.7 12 -2 417 
(Phase• 11 1.805 .6450 .541 3.069 
(Phase= 21 o• 
I Scale! t • 
Dependent Vartabte tfanyclottlngonhepann_heparmchanged 
Model (Intercept). Phase 
~- Set to lero be(ause ttus pararlH!ler i~ redundant 
b. Fixed at the dtsplayed value. 
llypothe>ts 1 eH 
Wald Chi-
Square dl 
l7 075 1 
7.830 I 
95''6 wald Confidence tmerval 
lor [Xp(81 
5iq. £•ptBI lower Upper 
000 .028 .009 .089 
.oos 6.079 1.71 7 21.5 20 
1 
Table 31: Odds Ratio of Effective Heparin Dose Change If Any Clotting Occurred (Binary Logistic 
Regression) 
Paramtter Estim.;ues 
95% Wald Confidence Interval Hypothesis Test 
Wald Cht-
Parameter B Sid. Error Lower Upper '>quare 
(lntercepr) - 4.682 1.0046 - 6.65 1 - 2 7ll 2 1 721 
(Phase• !) 5. 193 l.IZ96 2.979 7.407 21 135 
(Phase= 21 o• 
tS<ale) I b 
Depend em Vanable lfanyclorungonhep•nn hepartnchanged EFFECTIVE change 
ModeL tlntercep!J. Phase 
a.. Set to zero because thiS par.amEttr Is r~dundant. 
b. fixed'" the dtSpLwed value. 
df 
1 
l 
95'>; Wald Confidence Interval 
for [ xptBI 
Siq, EKO(BI Lower Upper 
000 009 .001 .066 
.000 l &0.000 19.669 1647.264 
l 
Furthermore, and as clotting events type 2 and 3 are more clinically considerable and 
important from a morbidity point of view, we repeated above analysis using only any 
clotting events type 2 or 3 during phase I versus phase II. The Odds ratio of changing 
heparin dose during phase I compared with phase II for any clotting events type 2 or 3 
was still higher but not statistically significant OR = 3.12; 95% CI: 0.62-15.8, P = 0.17 
(Table 32), and the OR of effective heparin dose change in phase I compared with phase 
II for any clotting events type 2 or 3 was also higher but not statistically significant (Table 
33, OR 2; 95% CI: 0.08-51.6, P = 0.68). However, since the P values were insignificant 
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and the 95% Cis were wide, we might have lacked power to pick up on a clinically 
meaningful difference. 
Table 32: Odds Ratio of Heparin Dose Change If Any Clotting Type 2 or 3 Occurred (Binary Logistic 
Regression) 
Par-ameter Es t imates 
95% Wald Confrdonce Interval 
Parameter g Std. Error Lower Upper 
(lntercepU 3.980 .7137 - 5.3 78 - 2.58 1 
!Phase= I I 1. 13 7 .8281 - .486 2.760 
1Phase=2l o• 
!Sea lei I b 
Dependent Vanabfe nanvclomngrype 2or3 _onheJWin_hepJrlnchange d 
Model Onter"ptl. Phase 
a. Set to zr:ro because th1~ parameter is redundant. 
b. fixed .lt the displayed v.1lue . 
Hypothesis Test 
Wald Chr-
Square df 
31.095 1 
1.884 1 
95'\f; Wald Confodence Interval 
for Exp{Bl 
Sig. £xp!BI Lower Upper 
.000 .019 .005 .076 
. 170 3.117 .615 IS 795 
I 
Table 33: Odds Ratio of Effective Heparin Dose Change If Any Clotting Type 2 or 3 
Occurred (Binary Logistic Regression) 
P~rilmtttr Estimates 
95">:. Wald Confidence Interva l 
9S% Wald Confidence Interval Hypottu~s is rest 
Wald Chr-
Parametor B Std. Error l ower Upper SQuare. 
(Intercept) 1.110E- 0 16 1.4142 - 2.772 2.772 .000 
!Phase= II .693 J 6583 - l.SS7 3.943 .175 
1Phaseu 2J o• 
I SCale! 1 b 
De pend e Ill V a rrable llanvclomngtyp e2 or 3 _ onheparrn_heparrnc hanged _EFFECTIVE 
Model. llmercepU. Phase 
.1. Set to zero because this puameter is redundJ.nt. 
b. nxed at the diSplayed va lue. 
df 
I 
I 
f0< Exp!BI 
S>g. (X p(Bl Lower 
1.000 1.000 .063 
.6 76 2.000 .078 
1 
In conclusion, changing heparin dose after any clotting events during phase I was 
significantly more likely to happen compared with phase II, but change was not 
Upper 
15.988 
SU9J 
significantly successful especially after more serious clotting events such as type 2 and 3, 
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even in phase I when initially we thought that routine monthly ACT monitoring would 
reduce the occurrence of clotting events and guarantee effective heparin dose change, 
achieving ACT target above 150, when change occurred. 
In order to predict the likelihood of any clotting events occurrence during phase I, we 
built a multivariable Logistic regression model using any clotting event occurrence as a 
dichotomous dependent variable while using age, gender (Male = 1), HD line (CVC = 1), 
peripheral vascular disease (PVD coexistence = 1 ), cancer (coexistence = 1 ), Aspirin 
(intake = 1 ), Plavix (intake = 1 ), and Coumadin (intake = 1) as covariate independent 
variables (Table 34). 
Table 34: Multivariate Analysis -Odds Ratio of Any Clotting per Phase I (Logistic Regression 
Model) 
Parameter (stimaces 
95':\, Wald Confidence Interval 
95% Wald Confidence lnterv•l Hypothesis Test tor Exp!B) 
Wald Chi-
Pa.ram@:t~r B Std. £rr01 LOWH Upper Square dl Slq £xpi81 LOW'e:r Upper 
(lnt~rcept) - I 009 9084 - 2 .790 771 1.234 I .167 .365 .061 2 163 
Age .002 .0135 - .024 .029 .030 1 .862 1.002 .976 1.029 
Gende.r ISO 4356 - .704 I 003 118 I 731 I 161 495 2.727 
HD_arcess .621 .4525 -.266 1.508 1.885 I . 170 1.861 . 767 4 .519 
Comorb PVO - . 369 .4850 -1.320 .581 .sao I .446 .691 267 1.788 
Comorb_Can<.er - 600 5132 -L646 ··~ I 268 I .260 54q 193 I 560 ASA . 5 76 ,4455 -.298 1 449 1.669 1 . 196 1.778 .743 4.258 
Plav1x 212 .6102 - .984 1.408 . Ill 1 .728 l.l36 .374 4 0 87 
Coumad1n - 1.009 1.1418 -3 .24 7 1.229 .780 I . J77 . 165 .039 3 .419 
!Scale! I • 
Dependent Variable Anyclonmg_phasel 
Model. (Intercept). Age. Gender. ttD_access. Comorb_PVD. Comorb_Ca.ncer. ASA. Plavb:. Coumadin 
a. FIXed allhe displayed value. 
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Hosmer and Lemeshow Test 
Step Chi-square df Sig . 
1 8.321 8 .403 
Although the Hosmer-Lemeshow Goodness of Fit Test (42) indicated support for our 
model since P value was higher than 0.05 (P = 0.4), none of the independent variables 
(Table 34) could predict the risk of clotting occurrence during phase I (P values were not 
statistically significant). Moreover, in a similar model trying to predict the likelihood of 
any clotting events type 2 or 3, we were unable to identify any independent variable that 
could predict the occurrence of clotting events type 2 or 3 (Table 35), although the 
Goodness of model fit ( 42) was appropriate (P = 0.19). 
Table 35: Multivariate Analysis- Odds Ratio of Any Clotting Type 2 or 3 per Phase I (Logistic 
Regression Model) 
Para_mtter Estimates 
9S% W,lld Confidence Interval 
9 5% W•ld Confidence lmervol Hypothe~IS T est for ExpH!l 
Wald Chi -
PararnetPr B Std . Error lower Upper Square dl Slg. ExpJBI lower Upper 
Hnterc(!pl) - 3 . 183 1.2794 - 5 .691 .6 75 6 .190 I .013 .041 003 .509 
Age .006 01 80 -.029 0 41 120 1 729 I 006 .97 1 1.041 
Gender 1.030 .6Z30 -.1 91 2 .151 2 .7JJ 1 .098 1.801 .826 9 .497 
tiD ucess 1.040 .5929 -.122 2.201 3 079 1 .079 2.830 .885 9 .047 
Comorb_PVD -.624 6593 - 1.917 668 897 1 .344 536 14 7 1.950 
Comorb_Cancer - 1.491 .8725 - 3 .201 .219 2.919 I .086 .225 .041 1.24) 
AlA .64 1 .5912 -.318 1.999 2-021 I . ISS 23 18 . 727 7.384 
Pia VI)( 1.001 .7>40 - .4 77 2.478 1.761 I . 185 2.720 .6 20 11.9 23 
Coumadin .3 27 1.22 54 - 2 .074 1 .729 .071 I .789 1.38 7 . 126 15.31 7 
CS<alel I ' 
Depend ent Variable Anyclottlng_type2orl_phaet 
Model (lntercepO, Age . Gender. HD_dccess.. Comorb .. PVO. Comorb_Cancer. ASA. PIJVJX, Coumadm 
.1 . Fbtl!d at the displayed value. 
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Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 11 .212 8 .190 
Due to a complex interaction between phases that will require complicated statistical 
analysis restricted by the limited data that we had, and after consulting with one of our 
Biostaticians, Dr. Bingshu E. Chen from the Cancer Research Institute at Queen's 
University, we could not build a multivariate logistic model that will combine both phases 
of the study to identify the independent variables that would be able to predict the 
occurrence of clotting. 
Consequently, we repeated above Logistic regression models to predict the likelihood of 
any clotting events and any type 2 or 3 events occurrence during phase II (Table 36, 37). 
The use of CVC line as a HD line was associated with a significant risk of any clotting 
events as well as type 2 or 3 events during phase II (OR 4.27; 95% CI: 1.5-12.13, P = 
0.006). Hosmer-Lemeshow Goodness of Fit Test indicated support for the models ( -l2) 
since P values were higher than 0.05 (P = 0.999). 
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Table 36: Multivariate Analysis - Odds Ratio of Any Clotting per Phase II (Logistic 
Regression Model) 
ParOl mtttr Estlmatos 
9~% \Yald Confidtnce lnt.rll•l 
9>» Wald Conlodence lnttrv•l Hypothesis Test for ExptBI 
WJid Chi 
Parameter B Std. Error Lower Upper Square df Siq. ExptBI Loy,er Upp er 
!Intercept) - 2.123 1.1444 -4 .766 - .280 4.860 I .027 .080 009 .756 
Agf .000 .0 169 -.033 .033 .000 I .991 1.000 .967 1.034 
Gender .701 .5358 -.349 1.751 1.713 I . 191 2.016 .705 5.763 
HD_olt<ess 1.45 I .5Jl9 .407 2.495 / .41 s I .006 4.lb7 l.SOZ 12.1l7 
Comorb_PVD .375 .1817 - .761 1.115 .•11 6 I .Sl9 1.416 .465 4.5 51 
Comorb_Ccln<er .698 .5608 - .441 1.33b 1.444 I .Z30 2.009 .644 6 .27l 
ASA -. 45 I . 55 4 7 - 1.538 .636 .661 I 416 637 .215 1 889 
Plavix .833 .651 1 -.443 2.110 1.639 1 201 UOI 64l 8.244 
Coumadnl 1.19 1 .9799 -.729 3.112 1.478 I .224 3 291 .482 22.461 
tl<alel 1. 
Dependent Variable Anyclottlng_phasen 
Model !Intercept). Age. Gender. HD_access. Comorb_PVO. Comorb_Cancor. ASA. Pla111•. Coumadm 
.1 . Fixed .u the displayed valut . 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 .942 8 .999 
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Table 37: Multivariate Analysis - Odds Ratio of Any Clotting Type 2 or 3 per Phase II 
(Logistic Regression Model) 
Parametttr Estimatts 
9Sli' W•ld Confid•n<e lruerv•l 
9S~ Wald Confidence lntrrvul HypotheSIS Ttst for Expl8) 
\Vald C~l 
Par>m•IPr B Std Error lower Upper Square df Siq. ExptBl Lower Uoper 
nncercept) -2 .523 1.1444 -4.766 -. 280 4.860 I .027 .080 .009 .756 
Age .000 .0169 -.033 .OH .000 I .991 1.000 .967 1.034 
Gender .701 .5358 -.349 1.75 I 1.713 I . 191 2.016 . 705 5.763 
HO_access 1.451 5329 .407 2.495 7 .• 1 s I .OOb 4 .267 l.SOl Il . l27 
Comorb_PVD .3 75 .5817 -.765 1.515 .416 I .519 1.456 .465 4.551 
Comorb_Cancer .698 .5808 -.441 1.835 1.444 I .230 2.009 .644 6 .273 
ASA -.~51 . 5 54 7 - 1.538 .636 .661 I .416 .637 .215 I 88~ 
Plavix .833 .65 II - .443 2.110 1.639 I .lOI 2.301 .642 8.244 
Cournadin 1.191 .9799 -.729 3.112 1.·178 I .224 3.291 .482 22 461 
IScalel I• 
Depend em Variable any<:lomng_type2or3_phasell 
Model (Intercept). 1\ge. Gender, HO_access. Comorb_PVO. Comorb_Cancer. /UA. Plav.-. Coumadln 
J . r lxed .u the dlspl.lyed value. 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 .942 8 .999 
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Bleeding Events: 
Similar to clotting events and since bleeding event counts have the Poisson distribution, 
and in order to identify whether the difference between bleeding event counts between 
phase I and II was statistically significant, we analyzed our data using Poisson 
Regression (Please refer to page 34 forfitrther details about Poisson Regression and 
incident rate ratio). 
There was a total of 28 bleeding events during phase I compared with 32 events during 
phase II (Table 7). Those events were further categorized depending on the bleeding type 
(Tnblc 7). Bleeding events type 2 (Defined as overt bleeding documented by diagnostic 
investigations within 4 hours from hemodialysis session) were not identified in either 
phase (0 events) while two type 1 bleeding events (Defined as overt bleeding documented 
by clinical examination within 4 hours from hemodialysis session) were identified only 
during phase I since no type 1 and no such bleeds occurred during phase II (Table 7). 
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Table 7: Bleeding Events During Phase I & II 
Bleeding 11 !2 3 4 , s I Total 
Type I I I 
Phase I 2 0 14 6 6 28 
Phase II 0 0 20 9 3 32 
The incident rate ratio for all bleeding events during phase I was 12% lower than during 
phase II but was not statistically significant (Table J g, IRR 0.88; 95% CI: 0.53-1.45, P = 
0.61). 
Table 38: Total Bleeding Events per Phase (Poisson Regression) 
Parameter Estimates 
91~ Wald Conftd~oc~ Interval Hypothesis Test 
P;u.lmeter 8 Std. Error Lower 
!lnter<ep U - 1.2 26 . 1768 -l.S 72 
!J>hase•ll - .131 .2 588 -.641 
[Phases 2] o• 
!S<alt) l b 
Dependent Var•dble Tot.11_81eedlng_Events 
Model !lntercoptl. Phase 
a Set to zero b~cause th1s p;uamettr is redunda.nr 
b. FIKed at the displayed value. 
Wala Cht-
Uppor Square d( 
-.879 48.068 I 
.3 74 .266 1 
9S'_) Wald Confidence Interval 
for ExpiB> 
Siq. Exp(Bl Lower Upper 
.000 .294 . 208 .41 s 
.606 .H71 .Ill 1.453 
I 
Since bleeding events type 1 and 2 did not occur during phase I and II (Table 7), we only 
compare the incident rate of bleeding event types 3, 4, and 5 that occurred during phase I 
and phase II. Bleeding events type 3 and 4 occurred less frequently during phase I 
compared with phase II, 30% and 33% less for type 3 and 4, respectively during phase I 
--
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(Table 39. 40), while type 5 occurred more frequently during phase I (2 X) compared 
with II (Table 41 ). However, none of the incident rate ratios of those bleeding event 
types were statistically significantly different across phases (Table 39. -Hl. -l l ), type 3 (P 
= 0.31), type 4 (P = 0.44), and type 5 (P = 0.33). 
Table 39: Total Bleeding Events Type 3 per Phase (Poisson Regression) 
Paramettr Estlma£es 
95% Wald Conhd~nct Interval 
Parameter B Std. Error Lower Upper 
HntercepO -1.696 . 22 36 - 2. 134 - 1.2 57 
[Phase• I I -.3 57 .3485 - 1.040 .326 
IPhase~ l l o• 
IS<ale) I " 
D~pendent Var •able Total .. blocdlng_ Type_ Three_per _Phase 
Model (Intercept!. Phase 
a. Set to zero because this parameter is redundant. 
b. F1xed at the diSplayed value. 
Hypothesis T < st 
Wald Chi-
Square dt 
s 7 soz 1 
1.0 45 I 
Sig. 
0 00 
.306 
Table 40: Total Bleeding Events Type 4 per Phase (Poisson Regression) 
Parameter Es l lmates 
95!0 Wald Confidence Inte rval 
Parameler B Std. Error Lower Up pel 
Unterceo!l -2 .494 .3333 - 3.147 - 1.841 
[Phas e • I I - .405 .5270 - l.HS .628 
[Pha5e~ ll o• 
<Scale) J " 
Dependent Vanable rotal .. bletdlng_type_tour_per_p t_phase•l 
Model (Intercept), Phase 
d . ~t to zero be<ause th1s pard meter IS redund.u1\. 
b. FiXPd at the displ.wed valt~e. 
HypothesiS Test 
Wald Chi-
Square df 
s s ' 986 I 
.592 I 
Sig. 
.000 
.442 
95"'1. \Vald Conf1dence Interva l 
for Exp!B! 
Exp(B) Lower Upper 
.183 .118 .284 
.700 .354 1.356 
1 
9 5~ Wald Confidence Intel val 
for ExptB) 
Exp!BI Lower Upper 
.0 83 .0 4 3 .159 
.667 .2H 1 .373 
I 
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Table 41: Total Bleeding Events Type 5 per Phase (Poisson Regression) 
Par.tmeter Esllmates 
95'1; Wald Confidence fmerv,,f 
95% Wafd Confidence Interval HypotheSIS Test for ExptB• 
Wa ld Chi-
Pan meter g Std. Error Lower Upper Square df Sig. ExpiBI Lower Upper 
(lntercepU -3 .593 .5774 -4.724 
IPhaso • ll .693 .7071 .693 
IPhas e-2) o• 
I Scale) 1 b 
Dependent Vanable. Total_b leed lng_ Type_FIVe_per _Phase 
Model !Intercep t). Phase 
a. ~t to zero becau~e th1~ parameter 11 redundant. 
b. Fi~ed at the disp layed value . 
-2 .46 1 38. 72 3 l .000 .02& .009 .OBS 
2.079 .96 1 1 .327 2.000 .sao 7.997 
1 
Moreover, since a few patients did not finish the study, as they were transplanted (x 4 
patients) or died (x 6 patients) before the end of the study (Table 2), those patients did not 
have the full study length of exposure. Consequently, those patients who did not 
complete the study may model bleeding event rates in this study over time. To 
accommodate for the bleeding events occurring to a particular length of observation, 
divided by time of exposure, Poisson regression with offset variable analysis was used 
to calculate event rates as events per unit time, allowing the observation window to vary 
for each time unit ( 40). 
Using offset variable analysis, there was no difference of the incident rate ratio of all 
bleeding events occurring during phase I compared with phase II (T:1blc 42 , IRR 0.94; 
95% CI: 0.54-1.66, P = 0.84). 
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Table 42: Total Bleeding Events per Phase (Poisson Regression- Offset Variable) 
Par-.meter Estimates 
95% Wald Confidence Interval Hypothesis Test 
Paramet@r B Std . Error Lower 
(Intercept) - 5.424 .2041 - 5.824 
[Phase= II -.059 .2887 -.625 
(Phase=2) o• 
!Sc-'llel I b 
Dependent Vanable. Any_Bieedm_per_Pattent_per Phase 
Mode l !lntercepO, Phase. offset ~ Months_of_FU 
a. Set to zero because this parameter 1s redundant. 
b . Fixed at the displayed value, 
Wald Cht-
Upper SQuare df 
- 5.024 706. 137 I 
.507 .042 I 
9 5% Wald Confidence Interval 
for ExplBl 
Sig. Exp(Bl Lower Upper 
.000 .004 .003 .007 
.838 .943 .53 5 1.660 
I 
Bleeding events type 3 and 4 occurred less frequently during phase I compared with 
phase II, 30% and 37% less for type 3 and 4, respectively during phase I (Table -B, 4-1-), 
while type 5 occurred more frequently during phase I (1.9 X) compared with II (Table 
45). However, none of the incident rates ofthose bleeding event types were statistically 
significantly different across phases (Table 43. 44. 45), type 3 (P = 0.23), type 4 (P = 
0.38), and type 5 (P = 0.37). 
Table 43: Total Bleeding Events Type 3 per Phase (Poisson Regression- Offset Variable) 
Para merer Es tim~ les 
95% Wald Confidence Interval 
Parameter g Std. Error Lower Upper 
!Intercept) -5 .607 .2236 - 6.0-15 - 5. 168 
(Phase• I) - .4 16 .3485 - 1.099 .267 
(Phase=2l o• 
(Scale) ,. 
Dependent Variable ToUI_bleedtng_ Type_ Three_per_Pha<e 
Model !Intercept!. Phase . ollset = Months_of_FU 
a. Set to zero btcau~e this pM.lmeter 15 redundant. 
b. Fixed at the displayed value . 
Hypothesos Test 
Wald Chi 
Square df 
628.670 I 
1.423 I 
95j(i Wald Confidence Interval 
for [Xp!BI 
Sig. Exp!BI Lower Upper 
.000 004 .002 .006 
.233 .660 .333 1.306 
I 
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Table 44: Total Bleeding Events Type 4 per Phase (Poisson Regression- Offset Variable) 
Par.ameter Es t imates 
95"> Wald Confidence lmerval 
95% Wald Confidence Interval 
Par meter B Std. Error lower Up per 
tlntercepu - 6.405 .3333 - 7 .058 - 5.7 52 
!Phase• I ) - .464 .5270 - 1.497 .569 
1Pha'"=2 l o• 
tSc.lel 1 b 
Dependent Variable Total_bleedlng_type_four _per_pt_phose' 1 
Model (lnte rceptl . Phase . offse t • Months_of_FU 
a . Set to ze ro be< a use th1s parameter IS redundant. 
b . Fixed at the displayed value. 
Hypothesis Test lor E'p iBI 
Wa ld Chi-
Square d l Siq. Exp tBI Lower 
369 .22 ~ L .000 .00 2 .00 1 
. 77 7 I .3 78 .6 28 .22 4 
1 
Table 45: Total Bleeding Events Type 5 per Phase (Poisson Regression- Offset Variable) 
Pu"meter Es timates 
Upper 
.003 
1.766 
9 5% Wald Confidence Interval 
95% Wa ld Confidence Inte rval 
Parameter 8 Sid. Error Lower Upper 
tlnterceptl -7.5 04 .577 4 - 8.6 35 
!Phase• I I .634 .707 1 -.752 
1Phase~2l o• 
<Scale ) Jb 
De pendent Va nable Total_bleed lng_Type_Frve_per_Pha se 
Mode l tlnterce ptl. Phase. offset • Months_OF_FU 
i1 Set to zero becau~e th1s paramerer 1s redundanr 
b . Fbed at the d rsplayed value . 
- 6.3 72 
2.020 
Hypothe SIS TeSt for ExpiBI 
Wald Chi · 
Square d f Sig . Exp!RI Lowe r Upper 
168 .9 16 I .000 .001 .000 .002 
.504 I .3 70 1.855 .472 7 .539 
I 
To evaluate the intrapersonal effects on bleeding events and in order to identify whether 
the difference between bleeding event occurrence, as a dependent categorical variable 
(Bleeding occurred; Yes = 1 or No = 0), between phase I and II was statistically 
significant, we analyzed our data using Binary Logistic Regression (Please refer to page 
41 for fi-trther details about Binary Logistic Regression, Odds Ratio and the inte1pretation 
of the width of95% confidence interval) . 
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The Odds Ratio (OR) of any bleeding event to occur in either phases was similar (Table 
-+6, OR I; 95% CI: 0.53-1.9, P = 1 ). 
Table 46: Any Bleeding Events Phase I versus II (Logistic Regression) 
Parameter Estlmares 
9~% Wald Contldence Interval 
95% Wald Confidence Interval HypotheSIS Test lor [ xptBl 
Wald Ch1-
Parameter 8 Sld. Error Lower llpptr ~uare df S!g f•pt8) LO'Ner Upper 
!Intercept) - 1.265 2312 -1 718 -812 29 .930 I 000 282 179 444 
{Phasea I) .000 .3269 - .64 1 .6•1 .000 I 1.000 1.000 .527 1.893 
)Phase= 2) o• I 
IS< ale) I h 
Dependent Varl.1ble Any_Bieedln_per_Patlent_per Phase -
Model. ttnter<eptl. Phase 
a. Ser ro zero btGtuse this pflramerer Is reduodanr 
b. Flxed at the d isplayed value. 
So, although all bleeding events occurred less frequently during phase I compared with 
phase II; 12% using Poisson regression (IRR 0.88) and 6% using Poisson regression with 
Offset variable analysis (IRR 0.94), differences were not statistically significant. 
Furthermore, since there was only 4 bleeding events during phase I, where heparin doses 
were changed and were effective (ACT post heparin dose change achieved a target ACT 
of 150 to 200), and only 3 events occurred during phase II, where heparin was changed 
without available post heparin dose change ACTs (Table ~),we did not statistically 
analyze our limited data to compare whether heparin dose was changed more often in 
phase I versus phase II. 
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Table 8: Bleeding Events and Heparin Doses Changes 
All Bleeding Events Heparin Changed 
00 (%) 
Phase I 28 4( 14%) 
Phase II 32 3 ( 9%) 
Effective Change 
ACT> 150 (%) 
4 (100%) 
No Available ACT 
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Secondary Endpoints: 
Since ACT, URR, and hemoglobin are continuous variables and since we have only one 
group of patients followed over the two phases of the study (two different conditions), we 
compared the mean of above variables of the two phases of the study analyzing our data 
using a Paired-samples t-test, assuming that the study sample was randomly selected from 
the hemodialysis population, study measurements observed were independent of one 
another and normally distributed with equal variances (-l2). With our large sample size (n 
= 109, > 30), violation of the last assumption was unlikely to cause any serious problems 
(43). 
With a 2-tailed significance level of0.05 (oc = 0.05) and a degree of freedom of 108 (n 
=109 - 1 =108), the mean baseline ACT in phase I (152.8 ± 18.7) was significantly 
higher than the baseline in phase II (139.9 ± 43.7), t (108) = 2.99, P = 0.003 (Table 47). 
The mean decrease in ACT was 12.79 with a 95% CI: 4.31-21.28 in phase II compared 
with phase I (Table 47). However, this statistically significant difference of 12.8 seconds 
in ACT is not clinically relevant. 
67 
Table 47: Paired Samples t-Test- ACT 
Paired Samples Statistics 
Mean N Std. Deviation Std. Error 
Mean 
Pair 1 
meanACT _phase I 152.758440 109 18.7438605 1.7953362 
meanACT phasell 139.964679 109 43.7170065 4.1873298 
Paired Samples Correlations 
N Correlation Sig. 
Pair 1 meanACT _phase I & 109 .161 .094 
meanACT _phasell 
Paired Samples Test 
Pa•red D1fftrences 
95% Confidence Interval ot 
Sid. Std . Error the 0 1fference Srq. (2 -
Mean Deviation Mt.lrl Lower I Upper t df taoled l 
Pair 1 meanACT phasel - 12.7937615 44 .7005194 4.281 S371 4 .307012 2 T 21.2 805107 2 988 108 003 
rneanACi _phase II 
To evaluate the effect of monthly routine ACT monitoring (intervention) on this 
difference, we calculate the intervention effect size for paired-sample t-test (known as Eta 
squared) reconm1ended by Cohen 1988 as the most conunonly used effect statistics (42). 
Eta squared= t2 + [t2 + (N-1)] 
Where tis the t-test value and N is the sample size (109 in our study) 
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Depending on Cohen 1988 guideline (42) the intervention effect size on the dependent 
variable will be small if Eta squared was 0.01 , moderate if Eta squared was 0.06, and 
large ifEta squared was 0.14. 
Eta squared was 0.08, reflecting a moderate effect of routine monthly ACT monitoring on 
the difference of the mean ACT between phase I and II (In other word<J, there was a 
difference in the mean ACT between phase I and II which could be secondary to routine 
monthly ACT monitoring). 
Repeating above analysis, the mean URR in phase I (70.50 ± 6.96) was significantly 
higher than phase II (66.16 ± 19.90), t (108) = 2.43, P = 0.017 (Table -+X). The mean 
decrease in URR was 4.35 with a 95% CI: 0.8-7.9 (Table 4:5). 
Table 48: Paired Samples t-Test - URR 
Pair 1 
Paired Samples Statistics 
Mean N Std. Deviation Std. Error 
Mean 
meanURR_phasel 70.5046 109 6.96118 .66676 
meanURR pha~s~ll~~66~. 1~5~68~--~10~9._ __ ~1~9~.8~99~5~2~---1~. 9~0~6~03~ 
.-------------P:...;:aired Samples Correlations 
N Correlation Si . 
Pair 1 meanURR_phasel & 109 _340 .000 
meanURR pha=s.:.:..ll ____ --'--------1---------l'---------' 
"-- -------------- - -- ---- -- - - - --
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Paired Samples Tes t 
P.1ired Differences 
95% Cont1den<e Interval of 
Std Std . [ rror the D•lference S1g (2 -
M~an oev•JUon Mean Lower I Upper ! df tailod) 
Pair 1 m~anURR_phdsel - 4.34780 18.71 188 I. 7Q227 
.79520 I 7.q OQ40 2 426 108 .0 17 
meanURR_phasll 
Eta squared was 0.05 reflecting a small to moderate difference in the mean URR between 
phase I and II, however, this difference was not necessarily due to ACT monitoring. 
Finally, the mean hemoglobin (Hgb) in phase I (114.11 ± 1 0.18) was significantly higher 
than phase II (105.6 ± 29.51), t (108) = 2.98, P = 0.004 (Table 49). The mean decrease in 
Hgb was 8.53 with a 95% CI: 2.85-14.21 (Table 49). 
Table 49: Paired Samples t-Test- Hemoglobin 
Paired Samples Statistics 
Mean N Std . Deviation Std. Error 
Mean 
meanHGB_phasel 114.11 16 109 10.18452 .97550 
Pair 1 
meanHGB phasell 105.5803 109 29.50928 2.82648 
Paired Samples c orrelat1ons 
N Correlation Sig. 
Pair 1 meanHGB_phasel & 109 .130 .177 
meanHGB _phasel l 
Paired S-ample s Test 
Paired D1fferen<~s 
95~. Conf!den(e Interval of 
Std . Std. [rror the Differen< e S1g. ll -
Mean Deviation Mean Lower I Upper t df called! 
Pair 1 meanHGB_pha>el - 8 .53128 29.93610 2.86736 2.847681 14.21489 2.9 75 108 .00~ 
m•anHr.8_pha<ell 
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Eta squared was 0.08 reflecting a moderate difference in the mean hemoglobin between 
phase I and II. However, the difference in the mean of hemoglobin, between phase I and 
II, could not be necessarily attributed to ACT monitoring. 
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DISCUSSION AND CONCLUSION 
After obtaining the ethical approval from the Human Investigations Committee and the 
Research Proposals Approval Committee (RP A C) of Eastern Health, a total of 109 adult 
chronic hemodialysis patients receiving heparin anticoagulation during their chronic 
hemodialysis, at established heparin doses at our hemodialysis unit, were enrolled and 
followed in our study, which represent a Quality Improvement Exercise, with a before-
and-after design. 
During the first four months of the study (Phase I), all patients received heparin as per our 
usual practice and heparin doses were expected to be adjusted, depending on the monthly 
routine ACT values, by the Nephrologist covering our hemodialysis unit as per our 
protocols (Appendix A & B). During the second four months of the study (Phase II), 
patients received heparin at a fixed dose, similar to the last bolus and maintenance doses 
delivered at the last HD session at the end of phase I. ACT-guided heparin dose 
monitoring was not done routinely during phase II; unless clotting or bleeding events 
occurred. If clotting or bleeding occurred at any point during phase II, heparin doses 
were expected to be adjusted by the Nephrologist covering the hemodialysis unit 
depending on a stat or a scheduled ACT value as per our protocols (Appendix A & B). 
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Patients' demographics and baseline characteristics were similar to chronic hemodialysis 
population in North America from age, gender, etiology ofESRD, and comorbidities 
points of view, as it was shown in table 1. Average age was 61.40 ± 15.99 years and 
almost 60% of patients were males. Diabetes and hypertension were the most cmmnon 
etiology of ESRD and both diabetes and hypertension were existed as comorbidities in 
most patients, as it was shown in table 1. Two third of the patients had dialysis lines, 
which is mildly higher than recommended. However, this high rate of dialysis line in our 
patients was mainly due to patients' personal preferences. 
The majority of enrolled patients completed the study. However, ten patients did not 
finish the study since six patients died and the other four received kidney transplantation 
before the end of the study. The average follow up of patients during phase I was 3.82 ± 
0.76 months compared with 3.7 ± 1.0 months during phase II. 
As it was expected, the mean ACT in phase I was significantly (P = 0.003) higher (152.8 
± 18.7) than phase II (139.9 ± 43.7), and heparin doses were changed more often and 
more effectively achieving ACT target during phase I compared with phase II. However, 
more than 50% of routine ACTs during phase I, were below target (ACT < 150), and 
heparin doses were unexpectedly changed only in less than 10% of these cases. 
Furthermore, heparin dose changes were unpredictably effective, attaining ACT target 
only in 50% of those cases where ACTs were low and heparin doses were changed. 
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Although the mean ACT level during phase I was significantly higher than phase II, and 
although heparin doses were changed more often and more effectively during phase I, all 
clotting events occurred unexpectedly and significantly more often during phase I 
compared with phase II. Even after compensating for the exposure time, using Poisson 
regression with offset variable analysis since a few patients did not finish the study, the 
incident rate ratio of all clotting events during phase I remained unexpectedly 41% 
significantly higher than in phase II (P = 0.041 ). This could be explained by the high 
prevalence of low monthly routine ACT values (ACT < 150) found in more than 50% of 
patients during phase I, combined with the low frequency of changing heparin doses (in 
less than 10% of those with low ACT during phase I), and finally by the low rate of 
effective heparin dose changes achieving a target ACT above 150, which occurred only in 
50% of the above cases during phase I. However, and although the above proposed 
mechanisms could be accountable for the high Odds ratio (OR = 1.87, P = 0.04) of any 
clotting event that could occur during phase I compare with phase II, they could not be 
the predominant contributors to clotting, since low ACT values were also observed in 
phase II with minimal effective heparin dose changes. 
Moreover, even when more serious clotting events occurred (clotting events type 2 and 
3), heparin dose change was not significantly more often or more successful during phase 
I compared with phase II. 
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As practiced locally, this could be due to doctors' responses to the ACTs. In our 
hemodialysis unit, doctors rotated on a monthly basis. In the first month of the study, 
more than halfofthe ACT values (57.8%) were below a target of ACT > 150. The doctor 
covering the hemodialysis unit during that month made a lot of heparin dose changes 
depending on routine ACT values. Even then, heparin dose changes, during that month, 
were surprisingly adjusted only in 55 .6% of low ACT cases, and dose changes were 
effective, achieving a target ACT of > 150, only in 51.4% of those cases. During the 
following three months of the study, and although ACT was low at < 150 in more than 
50% of routine ACT values, other doctors arbitrarily made very little changes, adjusting 
heparin doses in less than 10% of low ACT cases (3.2%, 11.1% and 7.8% during the 2"d, 
3rd and 41h month of the study). The above differences in the physicians' practices lead 
one to speculate that this might be due to the physicians' sense that tinkering with the 
heparin dose made little difference in their experiences. It might also attest to the 
challenge of regularly changing heparin doses to achieve targets in middle size to large 
hemodialysis units due to workload and other unstudied risk factors . However, a 
multicenter randomized trial or a large multicenter retrospective chart review study will 
be required to externally validate above finding before we can generalize our local 
doctors' response to ACT values, to the general Nephrology population. Furthermore, in 
future studies it would be advisable to have standardized heparin dose-adjustment 
protocols used routinely by hemodialysis nurses when either routine ACTs or event 
driven ACT values suggest a heparin dose adjustment. Doing so would reduce the 
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potential for bias due to physician variability in response to ACT data, especially in an 
open label study. 
In a multivariate analysis, we could not identify any significant specific risk factors that 
will increase the risk of clotting events, except for the use of hemodialysis eve I ines, 
which was associated with a significant risk of any clotting events as well as type 2 and 3 
clotting events during phase II but not phase I. With good multivariate models fit since 
the Hosmer-Lemeshow Goodness of Fit Test P values were above 0.05 (P = 0.999), the 
above finding further supports the proved benefits of arteriovenous fistula (A VF) 
compared with hemodialysis CVC line in chronic hemodialysis patients. Such a finding 
provides another rationale to encourage patients to accept A VF creation as an optimal 
dialysis access in chronic hemodialysis. 
The above findings related to clotting events were surprising and unexpected since we 
expected more clotting events to occur during phase II compared with phase I. Whether 
this resulted from doctors' response to ACT values and heparin dose changes in phase I, a 
failure to note and record some clotting events especially in phase II, the low number of 
clotting events, or other factors; was not very clear. 
However, we believe that since detecting and recording all clotting events as a routine 
part of nurses ' assessment during and at the end of each hemodialysis session as well as 
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ongoing education and encouragement of the hemodialysis unit's nurses, done 
periodically by Dr. Shamseddin during the study, minimizes the risk of missing clotting 
events during the study. 
Furthermore, prior to the study, we expected to have 5 clotting events per 100 patients 
over three months or 5 clotting events per 3,600 hemodialysis sessions. If these numbers 
were correct, the expected number of clotting events in our actual study, which had 109 
patients followed for 4 months, would be 7 clotting events per 109 patients or 7 clotting 
events per 5,232 hemodialysis sessions. Our study showed a total of 87 clotting events in 
phase I and 58 clotting events in phase II, both numbers were much higher than what we 
expected prior to our study. This is in line with our pre-study assumption that routine 
documentation of clotting events prior to the study would fail to capture all events. 
Furthermore, it also suggests that although the missing of clotting-related data could not 
be completely prevented in our study, data capture was definitely more complete during 
the study. It also indicates that diagnosing and recording clotting events in patients' 
records is feasible and should be a part of a routine assessment by hemodialysis nurses to 
be done during and at the end of each hemodialysis sessions. Furthermore, we believe that 
the recording system we invented and incorporated in our hospital computer (MEDitech) 
system was effective in capturing the majority of clotting events. However, if further 
studies were required in the future, the methods of capturing and recording clotting events 
has to be evaluated to avoid missing any data. 
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On the other hand, we identified a total of 28 bleeding events during phase I and 32 
events during phase II. Those events were further categorized depending on a specific 
definition into 5 different bleeding types (table 7). The incident rate ratio of all bleeding 
events during phase I, was 12% lower than phase II. However, this was not statistically 
significant and when we compensate for the exposure time, using Poisson regression with 
offset variable analysis, there was no significant difference in bleeding events comparing 
phase I with II. 
This was confirmed further by analyzing our data using logistic regression, which 
provided an Odds ratio of 1. This Odds ratio as well as the insignificant P value and the 
95% confidence interval, containing the value of 1, confinned that there was no 
significant difference in bleeding events comparing phase II with phase I. However, 
since the P values were insignificant and the 95% Cis were wide, we might have lacked 
power to pick up on a clinically meaningful difference. 
Furthermore, since there were only 4 bleeding events during phase I, following which 
heparin doses were effectively changed (ACT post heparin dose change achieved a target 
ACT of 150 to 200), and only 3 events during phase II, following which heparin doses 
were changed, but changes were unknown to be effective since ACTs were not available 
(Table g), we did not analyze our limited data to compare whether heparin dose was 
changed more often in phase I versus phase II. 
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The above findings related to bleeding events were surprising since we expected more 
bleeding events to occur during phase II compared with phase I. Whether this resulted 
from doctors' response to ACT values and heparin dose changes, missed bleeding events, 
the low number of bleeding events, or other factors; was not very clear. 
However, prior to the study, we expected to have 5 bleeding events per 100 patients over 
three months or 5 bleeding events per 3,600 hemodialysis sessions. If these numbers 
were correct, the expected number of bleeding events in our actual study, which had 109 
patients followed for 4 months, would be 7 bleeding events per 109 patients or 7 clotting 
events per 5,232 hemodialysis sessions. Our study showed a total of 28 bleeding events 
in phase I and 32 bleeding events in phase II, both numbers were much higher than what 
we expected prior to our study. This is in line with our pre-study assumption that routine 
documentation of bleeding events prior to the study would fail to capture all events. 
Furthermore, it also suggests that although the missing of bleeding-related data could not 
be completely prevented in our study, data capture was definitely more complete during 
the study. It also indicates that diagnosing and recording bleeding events in patients ' 
records is feasible and should be a part of a routine assessment by hemodialysis nurses to 
be done during and at the end of each hemodialysis sessions. Moreover, we believe that 
the recording system we invented and incorporated in our hospital computer (MEDitech) 
system was effective in capturing the majority of bleeding events. However, if further 
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studies were required in the future, the methods of capturing and recording bleeding 
events has to be evaluated to avoid missing any data. 
Regarding the secondary end points, we found that the mean urea reduction ratios (URR) 
and hemoglobin (Hgb) levels during phase I were significantly higher compared with 
phase II. However, the differences could not be clearly linked to higher and more 
effective ACT levels during phase I compared with phase II since the Eta squared were 
0.05 (small to moderate effect of ACT on URR), and 0.08 (moderate effect of ACT on 
Hgb) and the study design is open to many confounders affecting these outcomes. 
Strengths: 
Our study was the first and the only study that evaluated the effect of routine monthly 
ACT monitoring on major clinical events (clotting and bleeding) as well as laboratory 
parameters (clearance - URR and Hgb) in an ambulatory adult chronic hemodialysis 
population on an established heparin dose. It is a prospective study with a before-and-
after design. The sample size, the primary endpoint events occurred during the study, and 
the follow up were large and long enough to achieve our estimated power as reported 
above. The loss to follow up was less than 10% and offset variable analysis was used to 
compensate for the exposure tin1e. 
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Limitations: 
Generalizability may be affected by the single center nature of the study. However, our 
hemodialysis unit provided dialysis to stable ambulatory adult chronic hemodialysis 
patients, in a suitable geographical location reflecting typical characteristics of a North 
American hemodialysis population. This suggests that the findings might apply to other 
North American hemodialysis units, although multicenter trials are still required to 
confirm our findings. 
Furthermore, due to the design of our study, an observational study with before-and-after 
design and the absence of blinding since patients were infom1ed that ACTs will not 
routinely measured during the second phase, information bias could not be completely 
avoided. Reporting and data abstract biases were the main types of information bias we 
faced in our study, while the recall bias was not important in the study since patients did 
not have to recall exposure to heparin or primary and secondary end points, as those 
were observed, diagnosed, and recorded prospectively and mainly by our hemodialysis 
nurses. Furthermore, since patients acted as their own controls and had the same 
exposure to heparin although ACTs were not routinely done during the second phase, 
selection bias was not considered. Likewise, although the open label nature of our study 
could be subject to a potential bias favoring the monthly routine ACTs monitoring, our 
study analysis indicated that the efficacy effects of monthly ACTs monitoring was likely 
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not confounded by ascertainment bias since monitoring was not associated with better 
outcomes. 
Primary end points, specifically clotting events, were clearly defined and classified based 
on visual inspections of the dialyzer and hemodialysis circuit lines, that were evaluated 
routinely by the hemodialysis nurses during and at the end of each HD session and 
recorded regularly in the patients ' electronic chart using our hospital computer 
(MEDitech) system at the end of each HD session. Since nurses subjectively evaluated 
and scored events prior to recording them, reporting bias could not be avoided 
completely. However, since periodic education and encouragement to note and record 
event accurately were done by Dr. Shamseddin with our hemodialysis nurses during the 
study, we believe that the majority of events, including minor events, were diagnosed and 
recorded in patients' records. Moreover, the higher number of identified events that were 
observed during the study compared with those recorded prior to the study, confirmed 
that our developed protocol aided detection and recording the majority of events, reaching 
the stated study power. Alternatively, bleeding events were much more difficult to define 
and report, leaving a higher chance of missing data. A better definition of bleeding event 
and data collection would be required for future larger randomized controlled trials in the 
future. Furthermore, if our data are representative, in order to calculate sample size for 
future potential trials, it should be noted that clotting events were three times as frequent 
- ---------- ---------
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as bleeding events, which is different from the assumption we made in planning this 
study. 
In conclusion, routine monthly ACT monitoring in adult chronic hemodialysis patients 
was not associated with a reduction in clotting and bleeding events compared with 
measuring ACTs only for initial dose assignment or in response to clinical indications. 
Simultaneously, we believe that clotting and bleeding events in chronic hemodialysis 
patients in general are under diagnosed and unreported sufficiently in hemodialysis units. 
Defining those events clearly, noting and recording events as a part of a routine 
assessment that has to be done and documented regularly in patients' records, by the 
hemodialysis nurses during and at the end of each hemodialysis sessions, and ongoing 
education and encouragement of the hemodialysis nurses to observe, diagnose, and record 
events are required to enhance patients' care and management. 
Furthermore, although routine monthly ACT monitoring did not reduce the incidence of 
clotting and bleeding events in chronic adult hemodialysis patients, tailoring the best care 
plan to manage those events and avoid furthers events should be discussed individually 
with the local Nephrologist until multicenter randomized trials are available to confirm 
and generalize our findings. 
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Developing better objective definitions of clotting and bleeding events as well as more 
practical recording systems and strict standardized heparin dose-adjusting protocols to be 
used routinely by hemodialysis nurses as a part of routine intra- and postdialytic patient-
care assessment, have to precede before a future multicenter blinded randomized trial or a 
large multicenter retrospective chart review study, to externally validate our findings in 
order to improve generalizability and to reduce confounded physician response variability 
and biases. Expecting an incident rate of bleeding events at 1 :3 clotting events instead of 
1: 1 ratio has to be considered to calculate future sample size. Meanwhile, adopting our 
invented hospital computer system to assess and record clotting events, including minor 
events, should be practical until a better system is available. 
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Anticoagulation with unfractionated heparin is the usual way of 
preventing clotting in the extracorporeal system. Routine full dose 
heparin prescr iptions are for patients at normal risk for bleeding. 
POLICY 
•!> Hemodialysis patients either receive systemic heparin at full 
intensity, low intensity, or have heparin free dialysis . 
.:- Full intensity heparinization is the usual treatment. This is 
usually achieved by administration of a heparin bolus dose 3-5 
minutes prior to initiating dialysis followed by a continuous 
infusion . 
.:• Low intensity heparinization, or heparin free therapy may be 
implemented by the RN or a given dialysis session on the basis 
of his/her pre dialysis assessment (refer to policy for Low 
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Intensity or Heparin- Free Dialysis). 
The decision about what level of heparinization to use in subsequent 
dialysis sessions should be made in consultation with the 
nephrologist. 
Scope 
Registered nurses working in Dialysis Units within Eastern Health 
upon completion o Hemodialysis orientation 
Purpose 
To prevent or minimize clotting in the extracorpeal system, while also 
maintaininq an acceptable risk of bleedinq. 
Procedure 
1. Assess for any bleeding or potential risk for bleeding. 
2. Check patient's prescription or heparin if established 
and verify that this is appropriate to current bleeding 
risk. If so, follow this heparin prescription. Otherwise, 
follow the appropriate low intensity/heparin-free 
algorithm, either as ordered by the physician, or as 
judged appropriate to the current bleeding risk (see low 
intensity or heparin- ree policy). 
3. If bleeding risk is considered normal and there is not an 
existing prescription for full intensity heparin , please ask 
the responsible nephrologist or an appropriate initial 
heparin prescription , and then follow the assessment 
and dosing algorithm below. 
4. If using the algorithm or the current dialysis session, 
measure baseline ACT prior to heparin bolus. Please 
see section 8 for further details. 
5. Draw up bolus dose of heparin and attach to arterial 
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needle. 
6. Instill bolus dose 3-5 minutes prior to initiation of dialysis 
and once all dialysis needles have been successfully 
placed. 
7. Start continuous heparin infusion with initiation o 
dialysis. 
8. Heparin in usion rates are monitored. at least once per 
hour, during the dialysis treatment as part o the normal 
routine monitoring. 
9. The extracorporeal circuit is assessed at the same times 
for any visible signs o fibrin/clot formation . 
10. Discontinue infusion one hour prior to the 
discontinuation of dialysis unless otherwise ordered. 
11. During the rinseback procedure the extracorporeal 
circuit is assessed for any visible signs of clotting/fibrin 
formation . 
12. Record hemostasis time in patient's chart and notify 
nephrologist if prolonged. 
Procedure for patients with hemodialysis catheters 
Procedure is as above with the allowing exceptions: 
a) Follow catheter opening policy for administration o 
heparin bolus 
b) Continue heparin infusion until discontinuation o 
dialysis 
Heparinization during dialysis for patients already receiving 
heparin or low-molecular weight heparin IV or SC. 
If the patient is receiving an IV un ractionated heparin infusion 
or SC unfractionated heparin at therapeutic doses, no 
additional heparin will be required for dialysis. The protocol for 
95 
Eastern 
POLICY NAME 
A0::4/l0 
II a lth Appendix 
monitoring and adjusting the heparin as already ordered 
should be followed. 
If the patient is being treated with therapeutic doses of low-
molecular weight heparin (IV or SC), no additional heparin will 
be required for dialysis. The protocol for monitoring and 
adjusting the low-molecular weight heparin as already ordered 
should be fo llowed. 
If the patient is receiving low dose prophylactic unfractionated 
or low-molecular weight heparin SIC, continue with the usual 
dialysis heparin orders. 
Section 8: Determining the initial dose for full dose heparin 
therapy (see Flowsheet). 
1. Measure the baseline ACT pre dialysis. When access 
being used is a fistula or graft, draw the baseline sample 
directly from the 1stula needle prior to flushing the needle 
with 0.9% NaCI. Normal range in uremic patients can be 
68-132 seconds with a mean of 100 seconds. 
2. 1.5 to 2.0 times the patient's baseline number provides an 
ACT value range adequate or fu ll intensity heparinization 
for the majority of dialysis patients. 
3. Administer the ordered bolus dose of heparin. However, if 
the baseline ACT is greater than 150 further prolongation 
may be associated with bleeding and a bolus is not 
necessary. Omit the initial bolus of heparin in this case. 
4. Turn on the hourly heparin in usion. If the baseline ACT is 
greater than 150, reduce the hourly rate to 500-1 ,000 units. 
5. 15 minutes later, perform a 2ra ACT to determine the 
patient's response to the heparin bolus dose. The target is 
150-250 seconds. Re-bolus with 500- 1,000 units of 
heparin if the ACT is below the target range. I the ACT is > 
300, reduce the in sian to 500 units per hour until the 60 
minute ACT check. 
6. At 60 minutes into the dialysis treatment take a 3rd ACT to 
determine the effect of the hourly ra te. The tarQet ACT is 
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150-250 seconds. Increase the hourly rate by 500- 1.000 
units if the ACT is below the target range. Reduce the 
hourly rate by 500- 1,000 units if the ACT is above the 
target range. The hourly infusion rate will usually range 
from 500 units to 3,000 units depending on the patients' 
sensitivity to heparin. 
7. At 120 minutes take a 4t" ACT. The target ACT is 150-250 
seconds. The heparin dose may again be adjusted. 
Increase the hourly rate by 500- 1 ,000 units if the ACT is 
below the target range. Reduce the hourly rate by 500-
1,000 units if the ACT is above the target range. 
8. Note the time heparin will be stopped prior to the end of 
dialysis (usually 60 minutes for fistulae and grafts. end of 
dialysis session for catheters). 
9. At 180 minutes into treatment, take a 5th ACT unless you 
plan to stop heparin within the next 60 minutes. The target 
ACT at this stage is 150-180 seconds (reflecting the bolus 
wearing off and the anticipated end of dialysis session). 
The heparin dose may again be adjusted. Increase the 
hourly rate by 500- 1.000 units if the ACT is below the 
target range. Reduce the hourly rate by 500- 1,000 units if 
the ACT is above the target range. 
10. If hemostasis time was prolonged after needle 
removal in the last prior dialysis session or the system 
clotted out following heparin discontinuation, prior to 
discontinuing dialysis through either a fistula or AV graft on 
this occasion , take a final ACT to determine the effect of 
stopping the heparin infusion . The target ACT is 100-120 
seconds. 
11 . Document the clearance of the dialyzer and drip 
chambers. A reduced blood flow and/or multiple alarm 
situations can affect the condition of the dialyzer. 
12. Document the time for needle sites to stop bleeding. 
Acceptable time is s 10 minutes. 
13. In planning or second and subsequent dialyses 
using this protocol, consider the adjustments that had to be 
made during prior sessions in choosing the bolus and first 
hourly infusion rate. 
14. Complete at least 3 consecutive dialyses using this 
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protocol to determine the best bolus dose, hourly rate and 
stop time. If after 3 treatments, heparin dosage is still being 
adjusted, continue to do ACT testing until at least 1 
treatment is completed without changing the heparin dose. 
After that this protocol does not need to be followed unless 
clinical indications arise. 
If clinical indications of problems arise (e.g. clots noted in dialyzer 
or blood lines, or signs of bleeding) while the patient is being 
treated with a previously established heparin dose, this protocol of 
ACT checks and heparin dose adjustments should again be 
followed while giving the patient's usual initial bolus and irst 
hourly heparin dose, to determine whether further adjustments 
are now required. 
Guideline 
Normal intensity heparinization ACT range 150-250 sec 
Low intensity heparinization ACT range 100-150 sec 
Supporting Documents (Rai(Jr(Jncus. Jrrdusrry B(Jsr Pracucu. Leg,starton. ore} 
Nephrology Nursing Standards of Practice and Guidelines or Care 
ANNA 
Contemporary Nephrology Nursing: Principles and Practice, 
Second Edition-American Nephrology Nurses' Association 2006 
Linkages 
ACT CLP-150,Heparin-Low Intensity CLP-180,Heparin-free Dia lysis 
CLP-190 .Changing Dialyzer/Bloodlines TBS-01 0 
KeyWords 
ACT anticoagulation heparin system clotting 
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Hemodialysis Heparin Dosing Flowsheet- Full intenstty 
heparin 
Patient:. ____ _ 
Date Date Date 
Pre ! Time Pre Tim Pre 
ACT: 
=r· ACT: e ACT: - due 1 (Normal 68-132) (Normal 68-132} (Noi._mal 68-132) 
-Heparin bolus Heparin bolus Heparin bolus 
u u u 
Omit initial dose if Omit initial dose if Omit initial dose if >150 
>150 >150 Hourly rate__ _ u/hr 
Hourly Hourly 
rate u/hr rate u/hr 
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15 Min ACT: 
(Target 150-250) 
If ACT< 150 give 500-
1 ,000 u bolus 
If ACT> 300, reduce 
in usion to 500 u/hr 
Action taken: 
60 Min ACT: 
15 Min ACT: 
(Target 1 50-250) I 
I ACT< 1 50 give 500- I 1 ,000 u bolus 
I t ACT > 300, reduce 
infusion to 500 u/hr I 
Action taken: I 
I 
-
60 Min ACT: 
I 
(Target 150-250) (Target 1 50-250) 1 
if ACT<150- increase if ACT<150- increase 
hourly rate by 500- hourly rate by 500- I 
1
1,000 u I 1.000 u i 
if ACT >250 decrease if ACT >250 decrease J 
I 
hourly rate by 500- I hourly rate by 500- 1 
1 .ooo u 1,ooo u 1 I Action taken: I Action taken: I 
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T 15 Min ACT: 
(Target 150-250) 
If ACT< 150 give 500-
1 ,000 u bolus 
If ACT > 300, reduce 
in usion to 500 u/hr 
Action taken: 
60 Min ACT: 
(Target 150-250) 
if ACT< 150- increase 
hourly rate by 500-
1.000 u 
if ACT >250 decrease 
hourly rate by 500-
1,000 u 
Action taken: 
! 120 min ACT: I 120 min ACT: I 120 min ACT: 
I.,.,...,..----- I =----:--::-::---::-:::-::::-
1 (Target 150-250) (Target 150-250) I I (Target 150-250) 
1 if ACT<150- increase if ACT<150- increase 1 if ACT<150- increase 
hourly rate by 500- hourly rate by 500- i I hourly rate by 500-
1,000 u 1,000 u ! 11,000 u 
if ACT >250 decrease if ACT >250 decrease ; if ACT >250 decrease 
hourly rate by 500- hourly rate by 500- I hourly rate by 500-
1,000 u 1,ooo u 1 11.ooo u 
Action taken:----+--- Action t~en: -HI Action take_n __ = ____ 
1 
180 min ACT: 180 min ACT: I 180 min ACT: I 
(normal 150-180) (normal150-180) I (normal 150-180) 
if ACT< 150- increase if ACT <150- increase 1 if ACT< 150- increase 
hourly rate by 500- hourly rate by 500- hourly rate by 500-
' 1.ooo u 1.ooo u I 1.ooo u d 
if ACT >180 decrease if ACT >180 decrease if ACT >180 decrease 
hourly rate by 500- t}9urly_r'!te by 500- __._ _ _Jlourly _rate bi_ 500-
100 
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- -
1,000 u 1,000 u 
___ I ___ 
1,000 u 
Action taken: Action taken: Action taken: 
f- -- - ·-·------·-
Heparin stop Heparin stop Heparin stop 
time: time: time: 
I- If fistula or graft If fistula or graft If fistula or craft 
ACT pro ACT pre I ACT pre 
discontinuation: discontinuation: discontinuation: 
~-
-- --
(Target 1 00-120) 
(Target 100-120) (Target 100-120) 
----
Circuit clear? Circuit clear? Circuit clear? 
Art Art Art 
chamber chamber chamber 
-- -- -Dialyzer Dialyzer Dialyzer 
---Ven Ven Ven 
chamber chamber I chamber 
- -
1-
Sites held x 
--
min Sitesheldx ~ 1 Sites held x __ min 
Art Art Art 
X __ min x __ min X 
--
min 
Ven Ven Ven 
Plan for next Plan for next Plan for next treatment: 
treatment: treatment: Bolus: u 
Bolus: u Bolus: u Hourly rate: ufhr 
Hourly Hourly Stop time: 
rate: ufhr rate: u/hr 
Stop Stop dJ Completed by time: time: 1- Completed by: Completed by: 
--
RN _ RN __ RN 
---------- - --- ----------- -
---------
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Notes: 
1) Please complete or 3 consecutive treatments or until one complete 
treatment without adjustments 
2) Leave the worksheet in the Patient Chart 
3) Target ACT values provided are for Full intensity heparinlzation only 
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HEPARIN -LOW INTENSITY l 
Clinical Practice 
CLP-170 
lssulng Authority 
(sign & date) 
Office of Administrative 
Responsibility 
Author 
Level 
Original Approval Date 
Effective Date 
Review Date 
Revision Date(s) 
Overview 
Norma Baker Interim Chief 
Operating Officer 
Adult & Acute Care 
( St. John's) 
Dialysis Unit 
Cathy Cake Clinical Educator 
,Dr. Brendan Barrett Nephrologist 
Level two 
March/ 09 
March /09 
March /010 
Anticoagulation with heparin is the usual way o preventing clotting in 
the extracorpeal system. Routine full intensity heparin prescriptions 
are for patients at normal risk for bleeding. whereas dialysis with low 
intensity heparin or heparin tree dialysis may be prescribed in those at 
higher risk for bleeding. 
POLICY 
<+ Low intensity heparinization may be implemented by the RN for 
a given dialysis session on the basis of his/her pre dialysis 
assessment. 
•!• The decision about what level of heparinization to use in 
subsequent dialysis sessions should be made in consultation 
with the nephrotogists. 
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Scope 
Registered nurses working in Dialysis Units within Eastern Health 
upon completion of Hemodialysis orientation 
Purpose 
To prevent or minimize clotting in the extracorporeal system, while 
also maintainins:l an acceptable risk of bleeding. 
Procedure 
Procedure for patients with AV fistulas or grafts 
1. Assess for any bleeding or potential risk for bleeding. 
2. Check patient's prescription for heparin if established 
and verify that this is appropriate to current bleeding 
risk. If not, assess whether low-intensity heparin will be 
given as per this policy or heparin ree dialysis is 
required. Heparin free dialysis is indicated in the 
following clinical situations: 
•:+ Active pericarditis. 
<!• Recent surgery with bleeding complications. 
+:• Recent surgery after which bleeding would be very 
dangerous such as vascular, cardiac. retinal, brain and 
renal transplant. 
<• Severe coagulopathy (e.g. INR > 4 or PTT > 70 sees). 
•!• Severe thrombocytopenia (pits < 30). 
•!+ Intracerebral hemorrhage, or suspected increased risk of 
intracerebral hemorrhage due to a recent head injury. or 
severe hypertension (>200/115mmHg). especially w ith 
patients exhibiting changes in neurological status. 
•!• Any active bleeding not easily controlled prior to dialysis. 
•!• Recent patient ails with associated hematomas. 
•:• For dialysis within 24 hours of a new AV graft insertion or 
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revision, or insertion of a PD catheter. 
•!I Dialysis within 4 hours o arterial puncture (e.g. for 
angiography) . 
.:- Known or suspected heparin Induced thrombocytopenia 
3. Please consult with the responsible nephrologist if there 
is any concem or uncertainty about which heparin policy 
to apply. If the decision is to provide heparin free 
dialysis, please re er to the heparin ree dialysis policy, 
otherwise continue as below. 
4. If the patient already has an order for heparin intended 
to achieve full intensity ACT targets, reduce the bolus 
and infusion by 50%. If the patient does not have an 
existing order for a dose of heparin intended to achieve 
full intensity ACT targets please ask the nephrologist to 
provide an initial order appropriate to low-intensity 
heparinization. 
5. If using the algorithm or the current dialysis session . 
measure baseline ACT prior to heparin bolus. Please 
see section B for further details. 
6. Draw up bolus dose of heparin and attach to arterial 
needle. 
7. Instill bolus dose following cannulation o both needles 
3-5 minutes prior to initiation of dialysis. 
8. Start continuous heparin infusion with initiation o 
dialysis. 
9. Heparin infusion rates are monitored , at least once per 
hour, during the dialysis treatment as part o the normal 
routine monitoring . 
10. The extracorporeal circuit is assessed for any visible 
signs of fibrin/clot formation . 
11. Discontinue infusion one hour prior to the 
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discontinuation of dialysis unless otherwise ordered. 
12. During the rinseback procedure the extracorporeal 
circuit is assessed for any visible signs o clotting/ ibrin 
formation . 
13. Record hemostasis time in patient's chart and notify 
nephrologist if prolonged. 
Procedure for patients with hemodialysis catheters 
Procedure is as above with the allowing exceptions: 
a) Follow catheter opening policy for administration o 
heparin bolus 
b) Continue heparin infusion until discontinuation o 
dialysis 
Heparinization during dialysis for patients already receiving 
heparin or low-molecular weight heparin IV or SC. 
If the patient is receiving an IV unfractionated heparin infusion 
or SC unfractionated heparin at therapeutic doses. no 
additional heparin will be required or dialysis. The protocol for 
monitoring and adjusting the heparin as already ordered 
should be followed. 
If the patient is being treated with therapeutic doses of low-
molecular weight heparin (IV or SC), no additional heparin will 
be required or dialysis. The protocol for monitoring and 
adjusting the low-molecular weight heparin as already ordered 
should be followed. 
If the patient is receiving low dose prophylactic unfractionated 
or low-molecular weight heparin SIC, continue with the usual 
dialysis heparin orders for low-intensity heparinization. 
Section 8: Determining heparin requirements (see 
Flowsheet) 
1. Measure the baseline ACT pre dialysis. When access being 
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used is a fistula or graft, draw the baseline sample directly 
from the istula needle prior to flushing the needle with 
0.9% NaCI. Normal range in uremic patients can be 68-132 
seconds with a mean of 100 seconds. 
2. 1.0 to 1.5 times the patient's baseline number provides an 
ACT value range adequate or low intensity heparinization 
for the majority of dialysis patients. 
3. Administer the ordered bolus dose of heparin. However, if 
the baseline ACT is greater ttl an 100 urther prolongation 
may be associated w ith bleeding and a bolus is not 
necessary. Omit the initial bolus of heparin in this case. 
4 . Tum on the hourly heparin in usion. If the baseline ACT is 
greater than 100, reduce the hourly rate to 300-500 units. 
5. 15 minutes later, perform a 2rd ACT to determine the 
patient's response to the heparin bolus dose. This target 
should be within 100-150 seconds. Re-bolus with 500-
1.000 units of heparin if the ACT is below the target range. 
If the ACT is > 200, reduce the infusion to 300 units per 
hour until the 60 minute ACT check. 
6. At 60 minutes into the dialysis treatment take a 3rd ACT to 
determine the effect of the hourly rate. This target ACT 
should be within 100-150 seconds. Increase the hourly rate 
by 500- 1,000 units i the ACT is below the target range. 
Reduce the hourly rate by 500- 1 ,000 units if the ACT is 
above the target range. The hourly infusion rate will usually 
range from 300 units to 1 ,500 units depending on the 
patients' sensitiv ity to heparin and the heparin half-life. 
7. At 120 minutes take a 4r ACT. The target ACT should be 
100-150 seconds. The heparin dose may again be 
adjusted. Increase the hourly rate by 500- 1 000 units if the 
ACT is below the target range. Reduce the hourly rate by 
500- 1 ,000 units if the ACT is above the target range. 
8. Note the time heparin will be stopped prior to the end of 
dialysis (usually 60 minutes for fistulae and grafts. end of 
dialysis session for catheters). 
9. At 180 minutes into treatment, take a Slh ACT unless you 
plan to stop heparin within the next 60 minutes. The target 
ACT at ttl is stage is 100-130 seconds (reflecting the bolus 
wearinq off and the antic ipated end of dialysis session). 
108 
POLICY 'lAME 
Eas ern 
It a lth Appendix 8 
The heparin dose may again be adjusted. Increase the 
hourly rate by 500- 1 ,000 units if the ACT is below the 
target range. Reduce the hourly rate by 500- 1,000 units if 
the ACT is above the target range. 
10. If hemostasis time was prolonged after needle 
removal in the last prior dialysis session or the system 
clotted out following heparin disoontinuation, prior to 
discontinuing dialysis through either a fistula or AV graft on 
this oocasion, take a final ACT to determine the effect of 
stopping the heparin infusion. The target ACT is 1 00-120 
seconds. 
11 . Document the clearance of the dialyzer and drip 
chambers. A reduced blood flow and/or multiple alarm 
situations can affect the condition of the dialyzer. 
12. Document the time for needle sites to stop bleeding. 
Acceptable time iss 10 minutes. 
13. In planning or second and subsequent dialyses 
using this protoool, consider the adjustments that had to be 
made during prior sessions in choosing the bolus and first 
hourly in usion rate. 
14. Complete at least 3 oonsecutive dialyses using this 
protocol to determine the best bolus dose, hourly rate and 
stop time. If after 3 treatments, heparin dosage is still being 
adjusted, continue to do ACT testing until at least 1 
treatment is completed without changing the heparin dose. 
After that this protocol does not need to be followed unless 
clinical indications arise. 
If clinical indications of problems arise (e.g. clots noted in dialyzer 
or blood lines, or signs of bleeding) while the patient is being 
treated with a previously established heparin dose, this protoool of 
ACT checks and heparin dose adjustments should again be 
followed while giving the patient's usual initial bolus and first 
hourly heparin dose, to determine whether further adjustments 
are now required 
Guideline 
Normal intensity heparinization ACT range 150-250 sec 
Low intensity heparinization ACT range 100-150 sec 
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Not a Permanent Record 
Hemodialysis Heparin Kinetic Flowsheet· Low Intensity 
heparin 
due 
. ·ormal GS- IJ2} 
Hcparul bolus ___ u 
Omit initi at dose if ., I()() 
llourlyratc ___ u,1u ·-
I SMin ACT: 
. ·ormal 100-150) 
If ACT I 00 give S00- 1 ,000 u 
bolu 
If A > 100, rcduc•: infusion to 
300 ulh r 
if ACT <.J 00· incroasc hourh- rate 
by 500· 1.000 I • 
if ACT .> 150 decrease hourly ~ate 
by 500- 1.000 tl 
ct.lon takt n: 
120 m in ,\ Cf: 
(uonnaJ I 00-150} 
ifACT<. I 00- incr sc hourly m e 
by 500- 1.000 I I 
Date 
1me Pru 
duo ACT .. ~~--~------­
(:\oml31 6 -132 
Hcpa.ri:1 bolu• ____ u 
Omit i iti.ll dose tf >I CIO 
Hmut · rntc ___ u;hr 
IS Min ACT: 
. ·om~aii00- 150\ 
It ACT<. tOOgi ·c ~OO- I .OOOu 
bolus 
If ACT > 200. r ducc inftt>ion to 
J OO ullr 
T ime 
due 
Aclio!!J• k.,en"':'------------1--
60 M in ACT: 
{:-ormaii 00-1501-
if AC T•. ! 00· incrca. e hour\y rntc 
b~ 500- 1.000 u . 
if ACT , 150 dec rca•e ltou.rly rate 
b} 500· 1.000 ll 
Action u b n: 
I 20 m in ACT: 
(M mml 1 00·1 ~01 
if AC T I 00· incrC3sc hour.y rate 
by 500- 1.000 u 
if AC T • 150 drerca. c hou.rl)' rate 
b) 500-1.000 u 
~----~t\ctlonta~tn~:~------------+---
180 min ACT: 
Ardon ta k~n: 
180 min ACT: 
I lhlmlal I 00-U O_l_ 
ifACT< IOO- in ro.asc lhlurh· rotc 
by 500-1.000 I • 
if AC T .> 150 dcc rca>c hourly :ntc 
by S00-1 .000 u 
Action taktn: 
Hcpann stOJ) time. 
( llOntlal JQ0-1301 
if AC'T <. I 00· incn:-a•c houri y rate 
by 500-1 .000 u 
if ACT .• ISO dccrca. c ltour!y :ate 
by 500- 1.000 ll 
Action token: 
Heparin :-.lop um.c. _ -----
Date 
. 'o11nal 68- 132) . 
ll cpa rul bolus ____ u 
Omi: iniual d<>;.: if · 100 
Hourly rotc ___ w ht 
15 .\tln ACT: 
():Cirmal 100-150) 
I . ACT- I 00 . c500- l.OOO u 
bo.1lus 
If ACT ', 200. rcduc inftt>ion to 
300 u hr 
Action tak!!J: 
60 Min A 
C' onnal I 00- 150) 
if A T < I 00- i~cr~asc hourl~· rate 
b} 500-1.000 u 
if ACT .> 150 dccrc.»c hourly rate 
by 500- 1.000 u 
Actio n tak~n : 
120 min ,\ CT: 
(nom1al I 00-1 50) 
if ACT •.1 00· incroaso hourly rate 
by 500-1.000 u 
if A T -> 150 dcorca c hourly rate 
by 500- 1.000 u 
ctlon taktn : 
180 min ACT: 
( rlOnna I I 00· 130 I 
if AC'T< I 00· increase hourly ro:c 
b} 500-1.000 u 
if ACT > 150 dcorcasc ho r:y rate 
by 500· 1.000 ll 
Action tak~n: 
ll l!pa.nn ~lop time. 
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If fistula or ~;raft 
ACT pr~ dls~oDdnuatl&ll: __ 
(13rg t I 00- 120) 
Circui t clear? 
An clm nbcr 
Diaty7c-r _ _ -===--
V en cham[K~r 
:< _ mmVcn 
lfflstula or graft 
ACT pr~ dlsmntlnu8tlfln: 
{targct i 00-120) 
Circuit clear? 
Art chamber 
Dialyt..:-r ---~==--== V·n dlaJ~bcr__ ___ _ 
Stt"s h ldx min Art 
rnln \ rcn 
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If fistula nr gr aft I 
ACT prt> dlscomlnuat lon: __ 
Harg<t I 00- 120) 
Circui t clear? 
An chambe-r 
Di3lyzcr -------- __ 
Vcn cham· cr _____ _ _ 
Sites held x __ min A11: 
X min VCtl I 
Sttcs lteld x nun At! 
r-f-p[;r, fo~:~;c.i_u_c_a_t_m_c_o __ t -----l-----1 Plan (-,,-r·-.,-C-Xt_l_r_ca_l_m_c_n_t:---- - -1- ---- Plan for ni!.X_ l _lf_C_at_.m_CI-lt:----
1 
Bolus. u Bolus: u Bolus: u 
, 1-lourl>'<atc: _ __ ulhr H .wly ratc . ____ ulhr 1-lomlyratc-:-_.:::____u'hr I Stup u mc. Stopttmc._ _ Stopttmc. ___ _ 
[-- -:(:-:o·-~·-,-p:--!ctC'Il-:--, b:--)-,:- - - - - --- --- -----1-(-_.-o,-,-p·l-t~d bY:""--- --------1- - Eomplctcd b:;~-----------· 
I ----------------- R>; R~ ------- -- R~ 
'•h;tn 
I ) Pl;-:i~l; <n'f~C'h (-(u J ' ' llfl'l(''ul · -...; lrr,:;tl:-~;nt-.. ' .. rmt· l 1111: \'IIH!Ilh;h; •rnJ'rm.- , ... ~·•lhnul :t..lhr~lr-.;:nh 
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